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A B S T R A C T
Background
Many treatments for the common cold exist and are sold over-the-counter. Nevertheless, evidence on the effectiveness and safety of
nasal decongestants is limited.
Objectives
To assess the efficacy, and short- and long-term safety, of nasal decongestants used inmonotherapy to alleviate symptoms of the common
cold in adults and children.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 6, June 2016), which contains the Cochrane Acute
Respiratory Infections (ARI) Specialised Register, MEDLINE (1946 to July 2016), Embase (2010 to 15 July 2016), CINAHL (1981
to 15 July 2016), LILACS (1982 to July 2016), Web of Science (1955 to July 2016) and clinical trials registers.
Selection criteria
Randomised controlled trials (RCTs) and cluster-RCTs investigating the effectiveness and adverse effects of nasal decongestants compared
with placebo for treating the common cold in adults and children. We excluded quasi-RCTs.
Data collection and analysis
Three review authors independently extracted and summarised data on subjective measures of nasal congestion, overall patient well-
being score, objective measures of nasal airway resistance, adverse effects and general recovery. One review author acted as arbiter in
cases of disagreement. We categorised trials as single and multi-dose and analysed data both separately and together. We also analysed
studies using an oral or topical nasal decongestant separately and together.
Main results
We included 15 trials with 1838 participants. Fourteen studies included adult participants only (aged 18 years and over). In six studies
the intervention was a single dose and in nine studies multiple doses were used. Nine studies used pseudoephedrine and three studies
used oxymetazoline. Other decongestants included phenylpropanolamine, norephedrine and xylometazoline. Phenylpropanolamine
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(or norephedrine) is no longer available on the market therefore we did not include the results of these studies in the meta-analyses.
Eleven studies used oral decongestants; four studies used topical decongestants.
Participants were included after contracting the common cold. The duration of symptoms differed among studies; in 10 studies
participants had symptoms for less than three days, in three studies symptoms were present for less than five days, one study counted
the number of colds over one year, and one study experimentally induced the common cold. In the single-dose studies, the effectiveness
of a nasal decongestant was measured on the same day, whereas the follow-up in multi-dose studies ranged between one and 10 days.
Most studies were conducted in university settings (N = eight), six at a specific university common cold centre. Three studies were
conducted at a university in collaboration with a hospital and two in a hospital only setting. In two studies the setting was unclear.
There were large differences in the reporting of outcomes and the reporting of methods in most studies was limited. Therefore, we
judged most studies to be at low or unclear risk of bias. Pooling was possible for a limited number of studies only; measures of effect
are expressed as standardised mean differences (SMDs). A positive SMD represents an improvement in congestion. There is no defined
minimal clinically important difference for measures of subjective improvement in nasal congestion, therefore we used the SMDs as a
guide to assess whether an effect was small (0.2 to 0.49), moderate (0.5 to 0.79) or large (≥ 0.8).
Single-dose decongestant versus placebo: 10 studies compared a single dose of nasal decongestant with placebo and their effectiveness
was tested between 15 minutes and 10 hours after dosing. Seven of 10 studies reported subjective symptom scores for nasal congestion;
none reported overall patient well-being. However, pooling was not possible due to the large diversity in the measurement and reporting
of symptoms of congestion. Two studies recorded adverse events. Both studies used an oral decongestant and each of them showed that
there was no statistical difference between the number of adverse events in the treatment group versus the placebo group.
Multi-dose decongestant versus placebo: nine studies compared multiple doses of nasal decongestants with placebo, but only five
reported on the primary outcome, subjective symptom scores for nasal congestion. Only one study used a topical decongestant; none
reported overall patient well-being. Subjective measures of congestion were significantly better for the treatment group compared with
placebo approximately three hours after the last dose (SMD 0.49, 95% confidence interval (CI) 0.07 to 0.92; P = 0.02; GRADE: low-
quality evidence). However, the SMD of 0.49 only indicates a small clinical effect. Pooling was based on two studies, one oral and one
topical, therefore we were unable to assess the effects of oral and topical decongestants separately. Seven studies reported adverse events
(six oral and one topical decongestant); meta-analysis showed that there was no statistical difference between the number of adverse
events in the treatment group (125 per 1000) compared to the placebo group (126 per 1000). The odds ratio (OR) for adverse events
in the treatment group was 0.98 (95% CI 0.68 to 1.40; P = 0.90; GRADE: low-quality evidence). The results remained the same when
we only considered studies using an oral decongestant (OR 0.95, 95% CI 0.65 to 1.39; P = 0.80; GRADE: low-quality evidence).
Authors’ conclusions
We were unable to draw conclusions on the effectiveness of single-dose nasal decongestants due to the limited evidence available. For
multiple doses of nasal decongestants, the current evidence suggests that these may have a small positive effect on subjective measures of
nasal congestion in adults with the common cold. However, the clinical relevance of this small effect is unknown and there is insufficient
good-quality evidence to draw any firm conclusions. Due to the small number of studies that used a topical nasal decongestant, we were
also unable to draw conclusions on the effectiveness of oral versus topical decongestants. Nasal decongestants do not seem to increase
the risk of adverse events in adults in the short term. The effectiveness and safety of nasal decongestants in children and the clinical
relevance of their small effect in adults is yet to be determined.
P L A I N L A N G U A G E S U M M A R Y
Do nasal decongestants used alone relieve cold symptoms?
Review question
We wanted to find out if nasal decongestants used alone can ease nasal congestion symptoms in people with colds.
Background
Colds, although not serious, are common illnesses responsible for many visits to family doctors and days lost from work and school.
Cold symptoms include runny nose, sore throat and sneezing, and they can last up to two weeks. There is no cure for colds; treatments
only ease the symptoms. Many people use over-the-counter medicines such as nasal decongestants to treat cold symptoms. However,
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there is little evidence that nasal decongestants actually work. We wanted to find out if nasal decongestants help ease congestion caused
by colds.
We considered studies that used a nasal decongestant as the only treatment for colds. We looked at subjective symptoms of congestion
- this means that symptoms and overall well-being were self-rated by patients.
Search date
We searched for studies in July 2016.
Study characteristics
We included 15 studies with 1838 participants; 14 included only adults aged 18 years or over. Six studies used a single-dose nasal
decongestant and measured the effects on the day it was administered. Nine studies used multiple doses and the effects were measured
between one and 10 days after first administration. Eleven studies used tablets or syrup and four studies used nasal sprays. Eight studies
were conducted at universities, three at universities in collaboration with hospitals and two in hospitals. The setting was unclear in two
studies.
Study funding sources
Nine studies were funded by drug manufacturers or agencies with commercial interests in the study results. Funding sources were
unclear in six studies.
Key results
We were unable to draw conclusions about single-dose nasal decongestants. We found a small benefit in the relief of nasal congestion
from multiple doses, but it was unclear if this was beneficial for patients. No studies reported overall patient well-being. There was
no difference in the numbers of adverse events between people who used a nasal decongestant and those who did not. We could not
determine if there was a difference in effects between decongestant tablets and nasal sprays. The results relate to adults; there was no
evidence on the effectiveness or safety of nasal decongestants for children.
Quality of the evidence
We assessed the quality of the evidence for subjective cold symptoms as low for the multi-dose studies - there were few data and
reporting was unclear. We also assessed the quality of the evidence for adverse events as low because of unclear reporting and because
the estimates were not precise (there were wide confidence intervals - a measure of statistical uncertainty).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Should a single dose of decongestant in monotherapy be used for the common cold in adults?
Patient or population: adult pat ients with the common cold
Settings: common cold centres, universit ies and hospitals
Intervention: single-dose decongestant in monotherapy, oral and topical decongestants combined
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with single-dose
decongestant
Primary outcome:
subject ive symptom
score - 3 hours af ter
dosing
- - - 540 (4 RCTs, oral) - Insuf f icient data to pool
results
Pseudoephedrine
(Eccles 2005; Latte
2007; Taverner 1999)
; Phenylpropanolamine
(Cohen 1978)
Primary outcome:
overall pat ient well-be-
ing - 3 hours af ter dos-
ing
- - - (0 studies) - Not reported
Secondary outcome:
all adverse events
Two single-dose trials reported adverse events (
Gronborg 1983; Taverner 1999). Both used an oral
decongestant. Taverner 1999 (pseudoephedrine
versus placebo) reported no adverse events in
either the treatment or the placebo group; we did
not include Gronborg 1983 (norephedrine versus
placebo) results in the meta-analysis because a
cross-over study design was used and several
events per pat ient were reported
- 82 (2 RCTs, oral) - Insuf f icient data to pool
results
Norephedrine
(Gronborg 1983); Pseu-
doephedrine (Taverner
1999)
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* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; NAR: nasal airway resistance; RCT: randomised controlled trial
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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B A C K G R O U N D
Description of the condition
The common cold is viral in nature, afflicts individuals of all
ages and often necessitates utilisation of over-the-counter and pre-
scriptionmedications, and complementary interventions (Simasek
2007). Often caused by the rhinovirus, people typically experience
rhinorrhoea, sneezing, headache, nasal congestion, cough, fatigue
and pharyngitis (Eccles 2000).
Despite the common cold not being a serious condition, it has a
substantial impact in terms of time lost from work and school, as
well as money spent on both prescription and over-the-counter
medications (Heikkinnenn 2003). In the USA, the common cold
contributes to 22 million missed days from school and 20 million
absences from work annually, including days missed due to car-
ing for ill children (Pappas 2015). In Australia, upper respiratory
tract infections, nasal congestion, pharyngitis and cough consti-
tute 11% of all consultations in general practice (Fry 1993). In the
USA, there are 25 million visits to the family physician annually
due to the common cold and the total economic impact of the
common cold reached around USD 40 billion annually (Fendrick
2003).
Description of the intervention
Nasal congestion is one of the most uncomfortable symptoms ex-
perienced with the common cold (Fry 1993). There is no cure for
the common cold, therefore symptomatic therapy is the only treat-
ment option. Nasal decongestants are widely utilised for symp-
tomatic relief in both adults and children and can be administered
in oral or topical form (Del Mar 2003).
Decongestants may contain pseudoephedrine, phenylephrine,
oxymetazoline or xylometazoline. Nasal decongestants are avail-
able as tablets or nasal sprays or drops. They are mostly avail-
able over-the-counter without restrictions (Eccles 2009). It is rec-
ommended that they should not be given to children under the
age of six years (NPS Medicinewise 2012). Due to the risk of
rebound congestion after stopping use of decongestants it is ad-
vised that people should not use a decongestant for longer than
five days. Nasal decongestants mainly act locally but there may
be systemic effects, such as hypertension. Other common side
effects include headache, nausea, insomnia and dizziness (NPS
Medicinewise 2012).
People taking topical nasal or ophthalmic decongestants quickly
develop tachyphylaxis (a rapid decrease in the response to a drug
after repeated doses over a short period of time). Long-term use
is therefore not recommended, since the agents lose effectiveness
after a few days.
Previous reviews have considered the safety and efficacy of thera-
pies for indications including seasonal and perennial allergic rhini-
tis, chronic rhinitis, common cold and influenza (Dolansky 2008).
Many marketed treatments for the common cold exist and they
may consist of multiple active agents with claimed decongestant,
anti-secretory and anti-cough actions.
Heated, humidified air is one type of treatment intervention. The
mechanism of action includes the liquefying of mucus if it is dry,
thereby allowing it to be cleared more effectively. It also works by
the heat of the steam killing the cold virus that may be present in
the mucus. However, it is not routinely recommended as there is
insufficient evidence for its use (Singh 2013).
Corticosteroids are also used for the treatment of the common
cold and have been recently reviewed (Hayward 2015). Intranasal
ipratropium bromide has been reviewed and was found to be ef-
fective in reducing rhinorrhoea but ineffective in reducing nasal
congestion (AlBalawi 2013).
A Cochrane Review of saline nasal irrigation has reported limited
evidence of its efficacy in relieving symptoms of nasal secretion
and nasal congestion in upper respiratory tract infections (King
2015).
Combination medications have also been studied. For overall re-
covery it has been reported that combinations of antihistamines,
decongestants and analgesics have proven to be more effective
compared to placebo (De Sutter 2012). There was only a mod-
est effect of oral antihistamine-decongestant combinations, oral
decongestant-analgesic combinations and oral antihistamine-de-
congestant-analgesic combinations on nasal congestion. Only oral
analgesic combinations seemed to have no effect on the symptoms
of nasal congestion.
Since these medications for the common cold have already been
previously researched, this review will focus on nasal deconges-
tants.
How the intervention might work
Nasal decongestants are sympathomimetic amines that stimulate
the alpha-adrenergic receptors leading to vasoconstriction in the
blood vessels supplying the upper respiratory tract structures (NPS
Medicinewise 2012; Wicker 2009). This results in a net reduction
in oedema and nasal secretions and hence easier breathing.
Why it is important to do this review
This systematic review studied the efficacy and safety of nasal
decongestants in people with the common cold. This review will
provide evidence-based guidance to clinicians and people with the
common cold.
O B J E C T I V E S
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To assess the efficacy, and short- and long-term safety, of nasal
decongestants used in monotherapy to alleviate symptoms of the
common cold in adults and children.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included RCTs and cluster-RCTs or randomised cross-over
studies comparing nasal decongestants with placebo. We excluded
quasi-RCTs.
Types of participants
Adults and children of all ages and either gender with the common
cold, characterised by defined symptoms of an upper respiratory
tract infection (URTI), were eligible for inclusion. We included
participants who had symptoms for no more than seven days prior
to the start of the study. We excluded studies where another upper
respiratory condition (such as influenza, sinusitis or rhinitis) had
been diagnosed.
Types of interventions
Oral or topical nasal decongestants versus placebo (oral or spray,
as appropriate).
We included trials using topical and oral nasal decongestants ad-
ministered as aqueous spray, drops, dry powder, tablets or capsules.
We focused on nasal decongestants only, which work by stimulat-
ing the alpha-adrenergic receptors in upper respiratory tract blood
vessels, leading to vasoconstriction (Wicker 2009). We excluded
studies reporting combined interventions such as warm humidi-
fied air, steam, aromatic vapours, inhaled corticosteroids and in-
terventions using menthol.
Types of outcome measures
Primary outcomes
1. Subjective symptom scores for nasal congestion (self-
reported scores of congestion).
2. Overall patient well-being score (self-reported).
Secondary outcomes
1. Objective measures of nasal airway resistance (NAR).
2. Adverse events (for example, dry mucous membranes,
rebound congestion).
3. Complications (for example, sinusitis, otitis media, lower
respiratory tract infections).
4. Time to full recovery.
5. Time to return to school or work.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL, Issue 6 June, 2016), which contains the Cochrane
Acute Respiratory Infections (ARI) Specialised Register, MED-
LINE (1946 to July 15 July 2016), Embase (2010 to 15 July 2016),
CINAHL (1981 to 15 July 2016), LILACS (1982 to 15 July 2016)
and Web of Science (1955 to 15 July 2016).
We used the search strategy as outlined in Appendix 1 to search
MEDLINEandCENTRAL.We combined theMEDLINEsearch
strategy with the Cochrane Highly Sensitive Search Strategy
for identifying randomised trials in MEDLINE (Lefebvre 2011;
Appendix 1). We adapted the search strategy to search Embase
(Appendix 2), CINAHL (Appendix 3), LILACS (Appendix 4) and
Web of Science (Appendix 5). There were no language or publi-
cation restrictions.
Searching other resources
We searched www.clinicaltrials.gov and www.anzctr.org.au to
identify completed and ongoing trials (July 2016). We reviewed
reference lists and contacted researchers in the field to identify
further relevant studies. We contacted manufacturers of nasal de-
congestants for unpublished studies.
Data collection and analysis
This review is based on our published protocol (Ta’i 2012).
Selection of studies
Two review authors (LD, NM) independently reviewed and ap-
plied the inclusion and exclusion criteria to the titles and abstracts
identified by the search. We retrieved the full text if there was in-
sufficient information in the titles or abstracts to exclude a study.
Three review authors (LD, NM, LG) reviewed full-text articles,
ensuring that two review authors independently judged each arti-
cle. We consulted a fourth review author (MLvD) if there was any
discrepancy between the two authors and the issue was resolved
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by discussion. The review authors were not blinded to informa-
tion about the article, such as the journal title, the authors of the
articles or the results.
We recorded the selection process in sufficient detail to com-
plete a PRISMA flow diagram (Figure 1; Moher 2009) and
Characteristics of excluded studies table. We did not impose any
language restrictions.
Figure 1. Study flow diagram
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Data extraction and management
Three review authors (LD,NM, LG) independently extracted data
from all included articles using pre-designed data extraction forms.
A fourth author (MLvD) assisted in reaching a consensus if data
entries differed. We extracted the following data:
• First author, publication year, journal.
• Number, age and gender distribution of the patients
included in the trial.
• Case definitions (symptoms and measurements).
• Type, dosage, duration and route of administration of nasal
decongestant.
• Results (primary and secondary outcomes).
If a paper did not provide sufficient information about either study
details or results, we contacted the authors where possible.
Assessment of risk of bias in included studies
Three review authors (LD, NM, LG) independently assessed risk
of bias. We resolved disagreements by discussion with an arbiter
(MLvD). We assessed:
• random sequence generation;
• allocation concealment;
• blinding of participants and personnel (if relevant);
• blinding of outcome assessors;
• incomplete outcome data;
• dropout/selective outcome reporting; and
• other potential sources of bias.
We judged each potential source of bias as high, low or unclear and
provided a quote from the study report together with a justification
for our judgement in ’Risk of bias’ tables. We summarised the risk
of bias judgements across different studies for each of the domains
listed. We reported the risk of bias using the ’Risk of bias’ tool
from theCochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
Measures of treatment effect
We reported continuous data as the standardised mean difference
(SMD) because subjective and objective measures of congestion
were measured on different scales. The SMD adjusts for the dif-
ferences in measurement scales and enables data from different
scoring systems to be pooled; it is the absolute mean difference
divided by the standard deviation (SD). Dichotomous outcomes
were reported as odds ratios (ORs). SMDs and ORs were gen-
erated by RevMan software (RevMan 2014). We calculated 95%
confidence intervals (CIs) for each estimate.
Unit of analysis issues
We analysed the outcomes of the individual participants of each
trial. If the unit of randomisation was not the same as the level
of analysis (i.e. the individual participants), such as in cluster-
RCTs, we planned to make adjustments by taking into account
the impact of clustering as outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011).
If a trial included more than one treatment arm that was similar
(such as different doses of the same nasal decongestant), we com-
bined data from the treatment arms that were similar and com-
pared this group to the control group, as recommended in the
Cochrane Handbook for Systematic Reviews of Interventions, section
7.7.3.8 and Table 7.7a (Higgins 2011).
For studies using a cross-over design, we reported results separately
and did not include them in the meta-analysis.
Dealing with missing data
We were unable to obtain additional data from study authors
(many studies were quite old and authors could not be contacted).
Therefore, where possible, we compared studies that used an in-
tention-to-treat (ITT) analysis (assuming that all missing data rep-
resented unsuccessful outcomes) to those not reporting ITT anal-
ysis (on-treatment analysis) in a sensitivity analysis to assess the
potential impact of missing data on the overall effect of treatment.
Assessment of heterogeneity
We assessed heterogeneity in two ways. First, we explored the
presence of heterogeneity at face value by comparing population
groups, interventions or outcomes across studies. In the case of
clear face value heterogeneity we reported the outcomes of the
studies as in a systematic review but we did not pool the results.
If there was no obvious heterogeneity we used statistical tests such
as the Cochrane Chi² (Q) test and the I² statistic to determine
the presence and level of statistical heterogeneity for each outcome
(Higgins 2003). We considered an I² statistic of 60% or more to
represent important heterogeneity.Where possiblewe explored the
causes of statistical heterogeneity using subgroup and sensitivity
analyses. We specified a priori that we would not carry out a meta-
analysis if heterogeneity was greater than 90% and there was too
much variation in the results, particularly inconsistency in the
direction of the effect.
Assessment of reporting biases
We did not identify more than 10 studies for any of the outcome
measures. Therefore, it was not possible to assess reporting bias
using funnel plots as described in section 10.4.3 of the Cochrane
Handbook for Systematic Reviews of Interventions (Sterne 2011).
Data synthesis
We analysed single-dose and multi-dose studies separately as well
as combined. Clinically, we expect that a single or multi-dose of
nasal decongestant would have a similar effect, although it may
not be as long lasting in the case of a single dose. Therefore, we
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combined measurements of single and multi-dose studies for up
to three hours after dosing.
We included results from studies that met the inclusion criteria
and reported the selected outcomes in the meta-analysis. We cal-
culated the summary weighted OR and 95% CI for dichotomous
secondary outcomes using the inverse of the variance of each study
result for weighting. We standardised the results of the studies to
a uniform scale when looking at continuous outcomes. In this
case, we used the SMD to express the size of the intervention ef-
fect in each study relative to the variability observed in that study.
We planned to calculate the number needed to treat to benefit
(NNTB) for an additional beneficial outcome using the summary
OR and the average control event rate described in the relevant
studies. However, this was not possible because all studies assessed
improvement in nasal congestion on a continuous scale. We per-
formed fixed-effect meta-analyses and random-effects meta-anal-
yses and compared the two models. We reported any differences
between the models, but throughout all analyses we used a ran-
dom-effects model for final reporting.
There is no defined minimal clinically important difference for
measures of subjective improvement in nasal congestion, therefore
we used the SMDs as a guide. However, SMDs are difficult to
interpret and several options are available for re-expressing SMDs:
every method has its benefits and pitfalls. For this review we de-
cided to use rules of thumb for effect sizes as a guide: 0.2 to 0.49
represents a small effect, 0.5 to 0.79 a moderate effect and≥ 0.8 a
large effect, as described in section 12.6.2 of the Cochrane Hand-
book for Systematic Reviews of Interventions (Sterne 2011).
GRADE and ’Summary of findings’ tables
We created ’Summary of findings’ tables using the following out-
comes: subjective symptom scores for nasal congestion, overall pa-
tient well-being and adverse events.We used the fiveGRADE con-
siderations (study limitations, consistency of effect, imprecision,
indirectness and publication bias) to assess the quality of the body
of evidence as it relates to the studies that contributed data to the
meta-analyses for the prespecified outcomes (Atkins 2004).We in-
cluded the following comparisons: single-dose decongestant ver-
sus placebo, multi-dose decongestant versus placebo and all doses
versus placebo. We used the methods and recommendations de-
scribed in Section 8.5 and Chapter 12 of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011), using the
GRADEproGDT software (GRADEproGDT 2015).We justified
all decisions to downgrade or upgrade the quality of studies using
footnotes, and we made comments to aid readers’ understanding
of the review where necessary.
Subgroup analysis and investigation of heterogeneity
Wedecided a priori that, if sufficient data were available, we would
conduct the following subgroup analyses to explore differential
treatment effects.
• Children (aged up to 12 years) versus others (aged over 12
years).
• Topical versus oral nasal decongestants.
Sensitivity analysis
We decided a priori to perform sensitivity analyses to assess the
impact of heterogeneity on the overall outcome (pooled estimate)
of the meta-analysis. We did this by gradually removing single
trials to investigate the extent to which they contributed to het-
erogeneity. We also used sensitivity analyses to assess the impact
of risk of bias on the overall pooled estimate by first pooling the
studies with low risk of bias and then gradually adding the studies
assessed as having a high risk of bias.
R E S U L T S
Description of studies
All results are based on published data only. More informa-
tion about the studies is presented in Characteristics of included
studies, Characteristics of excluded studies, Characteristics of
studies awaiting classification and Characteristics of ongoing
studies.
Results of the search
We retrieved 888 records with duplicates removed from the
searches of the electronic databases (CENTRAL 285, MED-
LINE 364, Embase 427, CINAHL 70, LILACS 3 and Web
of Science 216). Based on screening of titles and abstracts, we
excluded 847 records; we assessed the full text of the remain-
ing 41 articles for eligibility (Figure 1). We excluded 25 stud-
ies based on the full text. Two studies have not yet been classi-
fied (NCT00452270; NCT01062360), and two studies are on-
going (EUCTR2006-006690-25-GB; NCT01744106). The rea-
sons for the exclusion of the 25 excluded studies are shown in
Characteristics of excluded studies table.
Included studies
We included 16 references to 15 RCTs (Eccles 2008 was published
as a full paper as well as an abstract). The interventions consisted
of single doses (N = 6) (Akerlund 1989; Cohen 1978; Ferguson
1997; Gronborg 1983; Latte 2004; Taverner 1999), and multiple
doses (N = 9) of nasal decongestants (Bye 1980; Eccles 2005;
Eccles 2006; Eccles 2008; Eccles 2014; Jawad 1998; Latte 2007;
Reinecke 2005; Sperber 1989). Some interventions included a
treatment arm with combination therapy (e.g. pseudoephedrine
plus paracetamol). However, in this review we focused on the
effectiveness of nasal decongestants only. Therefore, we did not
include the treatment arms that considered combination therapy.
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Design
The included trialswere randomised andplacebo-controlled.With
the exception of one (Jawad 1998), all trials were double-blinded.
Fourteen of the RCTs were parallel-group studies, and only one
cross-over design trial was included (Gronborg 1983).
Sample sizes
The included trials involved 2596 participants, including all treat-
ment groups, aswell as those receiving combination therapy.When
participants receiving combination therapy or other drugs (e.g.
paracetamol only) were excluded, the total number of participants
was 1838.
Setting
The studies were conducted in the United States (Cohen 1978;
Sperber 1989), United Kingdom (Bye 1980; Eccles 2005; Eccles
2006; Eccles 2008; Eccles 2014; Ferguson 1997; Jawad 1998),
Sweden (Akerlund 1989), Denmark (Gronborg 1983), Germany
(Reinecke 2005) and Australia (Latte 2004; Latte 2007; Taverner
1999). Six studies from the UK were conducted at the Com-
mon Cold Centre of Cardiff University (Eccles 2005; Eccles
2006; Eccles 2008; Eccles 2014; Ferguson 1997; Jawad 1998),
and the three Australian studies were conducted at the University
of Adelaide and the Royal Adelaide Hospital (Latte 2004; Latte
2007; Taverner 1999). The remaining studies were conducted in
a university (Gronborg 1983; Sperber 1989), or hospital setting
(Akerlund 1989; Cohen 1978). The setting was unclear in two
studies (Cohen 1978; Reinecke 2005).
Participants
The participants of six trials were recruited from the community
via poster advertisements (Eccles 2005; Eccles 2006; Gronborg
1983; Jawad 1998; Latte 2007; Taverner 1999), one of which only
advertised in a students’ magazine (Gronborg 1983). Two trials
recruited males undergoing military training (Akerlund 1989),
and staff from a charity foundation (Bye 1980). Recruitment pro-
cedures were unclear in seven trials (Cohen 1978; Eccles 2008;
Eccles 2014; Ferguson 1997; Latte 2004; Reinecke 2005; Sperber
1989).
With one exception, all studies included adult participants only
(Reinecke 2005). The cut-off in 10 studies was 18 years of age
(Akerlund 1989; Cohen 1978; Eccles 2005; Eccles 2006; Eccles
2008; Gronborg 1983; Jawad 1998; Latte 2004; Latte 2007;
Taverner 1999); five studies did not provide an age range (Bye
1980; Cohen 1978; Eccles 2014; Ferguson 1997; Sperber 1989).
In most trials the mean age was under 25 years (Akerlund 1989;
Eccles 2005; Ferguson 1997; Gronborg 1983; Jawad 1998; Latte
2004; Sperber 1989); mean ages were 26 years and 30 years re-
spectively in Taverner 1999 and Bye 1980. Six trials did not pro-
vide the mean age (Cohen 1978; Eccles 2006; Eccles 2008; Eccles
2014; Latte 2007; Reinecke 2005). Reinecke 2005 was the only
study to include younger people (participants had to be older than
12 years; however, the mean age of included participants was not
provided.
Thirteen studies clearly defined cut-offs for the time since on-
set of the common cold (Akerlund 1989; Cohen 1978; Eccles
2005; Eccles 2006; Eccles 2008; Eccles 2014; Ferguson 1997;
Gronborg 1983; Jawad 1998; Latte 2004; Latte 2007; Reinecke
2005; Taverner 1999). Ten studies used cut-off durations of less
than three days (Akerlund 1989; Cohen 1978; Eccles 2005; Eccles
2006; Eccles2008; Eccles 2014;Gronborg 1983; Latte 2004; Latte
2007; Reinecke 2005); three studies used cut-offs of less than five
days (Ferguson 1997; Jawad 1998; Taverner 1999). One study
counted the total number of colds over the period of a year and did
not specify the duration between onset of symptoms and enrol-
ment in the study (Bye 1980); another experimentally induced the
common cold via intranasal rhinovirus challenge (Sperber 1989).
The duration of follow-up varied from one to 10 days. All six sin-
gle-dose studies measured the effectiveness of a nasal decongestant
on the same day and, thus, had a follow-up of one day (Akerlund
1989; Cohen 1978; Ferguson 1997; Gronborg 1983; Latte 2004;
Taverner 1999). The remaining multi-dose studies had follow-
up of one (Jawad 1998), three (Eccles 2005; Eccles 2006; Eccles
2014), four (Latte 2007; Sperber 1989), or 10 days (Bye 1980;
Eccles 2008; Reinecke 2005).
Ten included RCTs clearly defined the inclusion criteria for cold
symptoms (Akerlund 1989; Eccles 2005; Eccles 2006; Eccles
2008; Eccles 2014; Ferguson 1997; Gronborg 1983; Jawad 1998;
Latte 2004; Taverner 1999). Six studies used an objective criterion
(e.g. nasal obstruction as measured by posterior rhinomanometry)
(Akerlund 1989; Eccles 2005; Eccles 2006; Eccles 2014; Ferguson
1997; Taverner 1999), whereas four trials used a certain num-
ber of symptoms or a subjective measure as cut-off (Eccles 2008;
Gronborg 1983; Jawad 1998; Latte 2004). Ferguson 1997, Bye
1980, Latte 2007 and Reinecke 2005 did not clearly describe a
diagnostic criterion.
Interventions
Nine trials used pseudoephedrine (Bye 1980; Eccles 2005; Eccles
2006; Eccles 2014; Jawad 1998; Latte 2004; Latte 2007; Sperber
1989; Taverner 1999), and three investigated oxymetazoline
(Akerlund 1989; Ferguson 1997; Reinecke 2005). Others used xy-
lometazoline (Eccles 2008), phenylpropanolamine (Cohen 1978),
or norephedrine (Gronborg 1983). However, in 2000, the US
Food and Drugs Administration (FDA) issued a public health ad-
visory recommending that phenylpropanolamine (also known as
norephedrine) should not be considered safe for over-the-counter
use and asked the drug manufacturers to voluntarily discon-
tinuemarketing products containing phenylpropanolamine (FDA
2000). As a consequence, phenylpropanolamine is no longer avail-
able as a decongestant in most countries. Therefore, we excluded
Cohen 1978 and Gronborg 1983 from the meta-analyses.
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Seven studies that used pseudoephedrine generally administered
multiple doses (Bye 1980; Eccles 2005; Eccles 2006; Eccles 2014;
Jawad 1998; Latte 2007; Sperber 1989), and all used oral tablets,
with the exception of Eccles 2014 and Sperber 1989 who used
granule sachets and oral capsules respectively. Of the remaining
six studies that did not use pseudoephedrine, four used a single
dose of medication (Akerlund 1989; Cohen 1978; Ferguson 1997;
Gronborg 1983). Only four studies used a topical decongestant
(Akerlund 1989; Eccles 2008; Ferguson 1997; Reinecke 2005).
See Table 1 for an overview.
Outcomes
Seven RCTs reported nasal airway resistance (NAR) as the pri-
mary outcome (Akerlund 1989; Cohen 1978; Eccles 2005; Eccles
2008; Gronborg 1983; Latte 2007; Taverner 1999). Two stud-
ies reported nasal airway conductance (NAC) as the primary out-
come, which is the inverse of NAR (Eccles 2006; Eccles 2014).
The benefit of NAC over NAR is that with NAC it is possi-
ble to collect data from participants with total nasal obstruction
(= zero conductance), whereas resistance would tend towards in-
finity. Other primary outcome measures were severity of subjec-
tive symptoms (Bye 1980; Sperber 1989), nasal nitric oxide lev-
els (Ferguson 1997), nasal volume (Latte 2004), minimum and
maximum airflow (Jawad 1998), and numbers of days until full
recovery (Reinecke 2005). NAR was measured by a rhinomanom-
etry test, which assesses nasal airflow obstructions by measuring
pressure and flow during normal inspiration and expiration. Most
studies used posterior rhinomanometry, where both nostrils are
measured simultaneously (Cohen 1978; Eccles 2005; Eccles 2006;
Eccles 2008; Eccles 2014; Ferguson 1997; Gronborg 1983; Latte
2007).Only one study used anterior rhinomanometry only, which
measures one nostril at a time (Akerlund 1989). Latte 2004 and
Taverner 1999 used both posterior and anterior rhinomanometry,
and Jawad 1998 used posterior rhinomanometry, but each nostril
was assessed separately by alternately occluding each nostril with
surgical tape.
Subjective symptom scores for congestion were often reported as
secondary outcomemeasurements (Akerlund 1989; Cohen 1978).
In total, 12 of 15 studies reported subjective symptom scores
for congestion (Akerlund 1989; Bye 1980; Cohen 1978; Eccles
2005; Eccles 2008; Eccles 2014; Gronborg 1983; Jawad 1998;
Latte 2004; Latte 2007; Sperber 1989; Taverner 1999). Subjective
symptom scores were either reported on a Likert scale of severity
(ranging from 4 to 7 points) (Akerlund 1989; Bye 1980; Cohen
1978; Eccles 2014; Gronborg 1983; Jawad 1998; Sperber 1989;
Taverner 1999), or on a 100mmvisual analogue scale (VAS)where
0 mm represented complete nasal patency and 100 mm repre-
sented complete nasal blockage (Eccles 2005; Eccles 2008; Latte
2004; Latte 2007).
Two studies also measured the time to onset of subjective relief
(Eccles 2008; Reinecke 2005), but other preselected outcomes
such as overall well-being, complications, time to full recovery and
time to return to school or work were not reported. Most included
studies also reported the frequency of adverse effects (Bye 1980;
Eccles 2005; Eccles 2006; Eccles 2008; Eccles 2014; Gronborg
1983; Latte 2007; Sperber 1989; Taverner 1999). Reinecke 2005
stated that adverse events were measured but these were not re-
ported.
Funding
NineRCTs clearly stated funding sources. Thesewere usually com-
mercial entities. Funding involved pharmaceutical companies such
as Pfizer Consumer HealthCare group (Eccles 2005; Latte 2007),
Procter and Gamble Company (Ferguson 1997; Taverner 1999),
Bayer HealthCare LLC (Eccles 2014), GlaxoSmithKline (Eccles
2006), Novartis (Eccles 2008), H. Lundbeck and Co (Gronborg
1983), Richardson-Vicks and the Aspirin Foundation of Amer-
ica (Sperber 1989). Five trials did not indicate sources of funding
(Akerlund 1989; Bye 1980; Cohen 1978; Jawad 1998; Reinecke
2005); the source of funding for Latte 2004 was not clear, but the
treatment medication was provided by Pfizer Consumer Health-
Care Group.
Excluded studies
We excluded 25 trials. Ten trials were excluded because the study
participants’ symptoms of nasal congestion or obstruction were
for reasons other than the common cold (e.g. allergic rhinitis)
(Akerlund 1989; Ashe 1968; Bailey 1969; Bende 1984; Bende
1985; Castellano 2002; Connell 1969; Pritchard 2014; Tzachev
2002; Zumpft 1975). We excluded five studies due to lack of ran-
domisation (Anderson 1956; Anonymous 1975; Katrana 1956;
McElhenney 1966; Smith 1999), three due to lack of a placebo
control group (Dorn 2003; Fox 1967; Meurman 1975), and
four because only combination therapy was used or reported
(Cohen 1977; De Paula Neves 1966; Rumiantsev 1993; Weisberg
1966). Other reasons included symptom duration of more than
six months (Broms 1982), and not measuring any of the prede-
fined outcomes (Hummel 1998; Winther 1983).
Ongoing studies
We identified two ongoing trials. Both are commercially funded,
double-blind RCTs involving participants with the common cold
and use of nasal decongestants. EUCTR2006-006690-25-GB is a
parallel-group study entered into the European clinical trials reg-
ister in 2007. This study investigates the changes in nasal con-
ductance in participants aged over 18 years with the decongestant
xylometazoline. No information on the expected end date of this
study was provided. NCT01744106 is a multicentre study that
began in November 2012 involving the response of nasal conges-
tion severity in children between the ages of six and 11 years to
the decongestant pseudoephedrine. The expected completion date
was April 2015, however, this was changed to May 2016.
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Studies awaiting classification
Two studies are awaiting classification (NCT00452270;
NCT01062360). Both are commercially funded, double-blind
RCTs involving the response of nasal congestion in participants
aged over 18 years with the common cold to nasal deconges-
tants (xylometazoline and pseudoephedrine). Although both stud-
ies were completed before 2011, we were unable to find their pub-
lished results.
Risk of bias in included studies
We assessed all included trials using the six specific domains de-
tailed in the Cochrane Handbook of Systematic Review of Interven-
tions ’Risk of bias’ tool (Higgins 2011). The results of this as-
sessment are shown for each study in Figure 2 and summarised
in Figure 3. Details of the included studies are presented in
Characteristics of included studies.Overall, most judgements were
unclear due to lack of detail provided in the trials reports. For ex-
ample, clear and detailed descriptions of the methods of sequence
generation, allocation concealment and blinding were often miss-
ing. Many studies also had pharmaceutical company funding of
unknown significance. We deemed only one study to be high risk
in any of the six domains (Jawad 1998); this was because the study
was not blinded and therefore assessed as high risk in both blind-
ing domains.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages for all included studies
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study
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Allocation
Random sequence generation
We assessed seven studies as low risk in this domain, as the authors
referenced a randomisation schedule or the method of sequence
generation was described in detail (Bye 1980; Cohen 1978; Eccles
2005; Eccles 2006; Latte 2004; Latte 2007; Taverner 1999). For
example, “Treatment randomisation was from a random numbers
table, in blocks of four” (Latte 2004).
We assessed the remaining eight studies as unclear risk for this do-
main because methods of random sequence generation were not
described (Akerlund 1989; Eccles 2008; Eccles 2014; Ferguson
1997; Gronborg 1983; Jawad 1998; Reinecke 2005; Sperber
1989).
Allocation concealment
The method of allocation concealment was poorly described, or
insufficient detail was provided to enable definitive judgement
on how concealment was achieved. We assessed five studies to be
low risk in the allocation concealment domain (Bye 1980; Cohen
1978; Eccles 2005; Eccles 2014; Latte 2004). For example, “it
was not possible to distinguish between combination product,
monotherapies, and placebo granules…they had the same appear-
ance, taste, and no noticeable smell” (Eccles 2014). We assessed
the remaining 10 studies as unclear risk because none provided the
methods of allocation concealment in the text (Akerlund 1989;
Eccles 2006; Eccles 2008; Ferguson 1997; Gronborg 1983; Jawad
1998; Latte 2007; Reinecke 2005; Sperber 1989; Taverner 1999).
Blinding
Blinding of participants and personnel
We assessed nine studies to be low risk in this domain as blind-
ing of participants and key study personnel was ensured and it
was unlikely that the blinding could have been broken (Bye 1980;
Cohen 1978; Eccles 2005; Eccles 2006; Eccles 2008; Eccles 2014;
Gronborg 1983; Latte 2004; Taverner 1999). For example, “the
randomisation code was not broken until all data, including de-
layed adverse events, had been allocated” (Taverner 1999). We
assessed five studies as unclear risk because insufficient informa-
tion was provided to permit a judgement of risk (Akerlund 1989;
Ferguson 1997; Latte 2007; Reinecke 2005; Sperber 1989). We
assessed the remaining study as high risk because the it was not
blinded (Jawad 1998).
Blinding of outcome assessment
We assessed two studies to be low risk in this domain as both
had stated methods of blinding of outcome assessment (Eccles
2014; Gronborg 1983). We assessed 12 studies as unclear risk, be-
cause there was insufficient information on the methods of blind-
ing outcome assessment to permit judgement (Akerlund 1989;
Bye 1980; Cohen 1978; Eccles 2005; Eccles 2006; Eccles 2008;
Ferguson 1997; Latte 2007; Latte 2004; Reinecke 2005; Sperber
1989; Taverner 1999). We assessed the remaining study as high
risk because it was not blinded (Jawad 1998).
Incomplete outcome data
We assessed 10 studies to be low risk for this domain. All partic-
ipants, including those who discontinued, were accounted for in
the text and the authors clearly indicated the numbers of remain-
ing participants per treatment group (Akerlund 1989; Bye 1980;
Cohen 1978; Eccles 2006; Eccles 2008; Ferguson 1997;Gronborg
1983; Latte 2004; Sperber 1989; Taverner 1999).We assessed five
studies as unclear risk (Eccles 2005; Eccles 2014; Jawad 1998;
Latte 2007; Reinecke 2005). Numbers of remaining participants
in each treatment group could not be ascertained.
Selective reporting
We assessed 12 studies as low risk for selective reporting; these
studies reported all intended outcomes (Akerlund 1989; Cohen
1978; Eccles 2005; Eccles 2006; Eccles 2014; Ferguson 1997;
Gronborg 1983; Jawad 1998; Latte 2004; Latte 2007; Sperber
1989; Taverner 1999). We assessed three studies to be at high
risk of selective reporting bias (Bye 1980; Eccles 2008; Reinecke
2005). Bye 1980 reported only significant results in detail; Eccles
2008 reported NAC rather than NAR (Eccles 2008).
Other potential sources of bias
We assessed four studies to be at low risk of other potential sources
of bias; there was no evidence of pharmaceutical company funding
or any other sources of bias identified in these studies (Akerlund
1989; Cohen 1978; Jawad 1998; Latte 2004). We assessed 11
studies to be unclear risk; nine reported receiving pharmaceutical
company (Eccles 2005; Eccles 2006; Eccles 2008; Eccles 2014;
Gronborg 1983; Latte 2007; Sperber 1989) or commercial fund-
ing (Ferguson 1997; Taverner 1999). Reinecke 2005 was described
very briefly and there was not enough detail to exclude the pos-
sibility of other bias. In Bye 1980, participants were monitored
for a six-month period and had between one and four colds in
this time. It is not clear from the text if participants with multiple
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colds were re-randomised to a treatment group or continued on
their original assigned treatment.
Effects of interventions
See: Summary of findings for themain comparison Summary of
findings for single-dose nasal decongestant compared to placebo in
adults with the common cold; Summary of findings 2 Summary
of findings for multi-dose nasal decongestant compared to placebo
in adults with the common cold; Summary of findings 3
Summary of findings for all doses of nasal decongestant compared
to placebo in adults with the common cold
See Summary of findings for the main comparison, Summary
of findings 2 and Summary of findings 3 for the primary out-
come, subjective symptom scores for nasal congestion, and our
main comparisons: single-dose nasal decongestant versus placebo,
multi-dose nasal decongestant versus placebo and all doses of nasal
decongestant versus placebo.
There was considerable variability in the way outcomes were re-
ported. The primary outcome, subjective nasal congestion, was
measured on Likert or visual analogue scales (VAS) with different
levels. Similarly, the secondary outcome, objective measurement
of nasal congestion, was reported as the mean nasal airway resis-
tance (NAR) (Akerlund 1989; Eccles 2005), the mean difference
of NAR (Cohen 1978; Taverner 1999), the area under the curve
(AUC) for the different NAR measurements from baseline to a
certain follow-up (Latte 2004; Latte 2007), the mean nasal air-
way conductance (NAC) (Eccles 2006; Jawad 1998), and the least
square mean of NAC (Eccles 2008). NAC is the inverse of NAR,
however the methods of calculating the NAC were not described,
making it impossible to recalculate the NAR or vice versa. Given
these differences, we were unable to combine different statistical
representations (e.g. mean and mean difference) as described in
section 9.4.5 of the Cochrane Handbook for Systematic Reviews of
Interventions (Sterne 2011). Therefore, results are presented for
each outcome type separately and only SMDs are presented for all
analyses to enable straightforward comparison of the effect size.
In some studies a positive score indicated better nasal patency,
whereas in other studies a negative score reflected better function-
ing. We transformed the negative scores (e.g. by multiplying by -
1) so that for all comparisons a higher score reflected better func-
tioning and studies could be combined. One study included more
than one treatment arm (four different doses of the same nasal
decongestant); we combined data from treatment arms that were
similar and compared this group to the control group (Akerlund
1989).
Heterogeneity was not greater than 90% for any analyses. We
tested and reported differences between using fixed-effect and ran-
dom-effects models, but we applied the random-effects model as
the final model for all analyses. The random-effects model gener-
ates wider confidence intervals (CIs) than the fixed-effect model
(Higgins 2011).
We present results for single and multi-dose studies separately as
well as all dosages combined for each outcome. We evaluated the
effectiveness of a nasal decongestant compared to placebo approx-
imately three hours after the last dose. We chose the timeframe
of three hours because clinically we expect that a single or multi-
dose of nasal decongestant would have a similar effect, although
it may not be as long lasting in the case of a single dose. Further-
more, most multi-dose studies measured nasal decongestant effec-
tiveness approximately three hours after the last dose. We discuss
the results for this comparison only where both single and multi-
dose studies were available for the same outcome. Otherwise, we
refer to the results for single or multi-dose comparisons separately.
Furthermore, some multi-dose studies also reported outcomes af-
ter a single dose. In this comparison only the results after multiple
doses are included otherwise the study would be counted twice.
If possible, we also present results for studies that used an oral or
topical decongestant separately and combined.
Primary outcomes
1. Subjective symptom scores for nasal congestion (self-
reported scores of congestion)
1.1. Single-dose decongestant versus placebo
Six trials were single-dose studies (Akerlund 1989; Cohen 1978;
Ferguson 1997; Gronborg 1983; Latte 2004; Taverner 1999), two
used a topical decongestant (Akerlund 1989; Ferguson 1997), and
four used an oral decongestant (Cohen 1978; Gronborg 1983;
Latte 2004; Taverner 1999). Four of the nine multi-dose studies
also reported results after a single dose of nasal decongestant (Eccles
2005; Eccles 2006; Eccles 2008; Latte 2007). Of these multi-
dose studies, only Eccles 2008 used a topical decongestant. As
such, 10 studies compared a single dose of nasal decongestant
with placebo, three of which used a topical decongestant. We have
differentiated between single-dose studies and studies reporting
after a single dose. The effectiveness of the nasal decongestant was
tested between 15 minutes and 10 hours after dosing. Given the
large diversity in time points and methods we were unable to pool
results. Results for all time points are reported in more detail for
each study separately in the following sections.
1.1.1 10 or 15 minutes after dosing
Two studiesmeasured the immediate effect of a nasal decongestant
versus placebo 10 minutes (Akerlund 1989, topical decongestant)
or 15 minutes (Cohen 1978, oral decongestant) after a single ad-
ministration. We were unable to pool results because Cohen 1978
was excluded from all meta-analyses. For both studies, the esti-
mated standardised mean difference (SMD) between treatment
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and placebo was statistically significant and in favour of the treat-
ment group (SMD 0.88, 95% CI 0.23 to 1.53; 40 participants;
Cohen 1978, oral decongestant) (SMD 0.51, 95% CI 0.03 to
0.99; 106participants; Akerlund 1989, topical decongestant). The
SMDs corresponded to a large and moderate effect respectively.
1.1.2 30 minutes after dosing
Two studies assessed the effectiveness of treatment after 30 min-
utes (Cohen 1978; Taverner 1999). Both studies used an oral de-
congestant. We were unable to pool results because Cohen 1978
was excluded from all meta-analyses. Only for Cohen 1978 was
the estimated SMD between treatment and placebo statistically
significant and in favour of the treatment group (SMD 0.88, 95%
CI 0.23 to 1.53; 40 participants; Cohen 1978, oral decongestant)
(SMD 0.46, 95% CI -0.09 to 1.01; 52 participants; Taverner
1999, oral decongestant). SMDs corresponded to a large and small
effect respectively.
1.1.3 One hour after dosing
Three studies measured the effectiveness of a nasal deconges-
tant subjectively one hour after dosing (Akerlund 1989; Cohen
1978; Taverner 1999). However, we were unable to pool results.
Akerlund 1989 used a topical decongestant and showed a small
clinical effect that was not significantly different between treat-
ment and placebo (SMD 0.22, 95% CI -0.25 to 0.70; 106 partic-
ipants; Akerlund 1989, topical decongestant). Cohen 1978 and
Taverner 1999 used an oral decongestant and showed a large and
moderate clinical effect that was statistically significant (SMD
0.88, 95% CI 0.23 to 1.54; 40 participants; Cohen 1978, oral
decongestant) (SMD 0.72, 95% CI 0.15 to 1.28; 52 participants;
Taverner 1999, oral decongestant).
1.1.4 Two hours after dosing
Three studies reported the effectiveness of a nasal decongestant
compared to placebo two hours after treatment (Cohen 1978;
Latte 2004; Taverner 1999). All three studies used an oral decon-
gestant. However, we were unable to pool results. In Latte 2004
and Taverner 1999, the estimated SMD between treatment and
placebo was not significant (SMD -0.10, 95% CI -0.66 to 0.47;
48 participants; Latte 2004, oral decongestant) (SMD 0.53 95%
CI -0.03 to 1.08; 52 participants; Taverner 1999, oral deconges-
tant). Only Cohen 1978 showed a large clinical effect that was
statistically significant (SMD 0.88, 95% CI 0.23 to 1.54; 40 par-
ticipants; Cohen 1978, oral decongestant).
1.1.5 Three hours after dosing
Four studies reported on the effectiveness of a nasal decongestant
compared to placebo three hours after dosing (Cohen 1978; Eccles
2005; Latte 2007; Taverner 1999). All four studies used an oral
decongestant. Again, we were unable to pool results. Eccles 2005
did not provide baseline values and there was insufficient informa-
tion to standardise the results for comparison with the other stud-
ies. Eccles 2005 found that the AUC of the VAS between 0 and
3 hours was significantly lower for the treatment group compared
to placebo participants after a single dose (P = 0.029; difference
in VAS AUC -8.33, 95%CI -15.80 to -0.85; 236 participants;
Eccles 2005, oral decongestant).However, Latte 2007 showed that
the AUC of subjective congestion was not significantly different
for the treatment group compared to the placebo group (SMD
0.22, 95% CI -0.05 to 0.49; 212 participants; Latte 2007, oral
decongestant). In Cohen 1978 and Taverner 1999, the estimated
SMD between treatment and placebo was not statistically signifi-
cant (SMD 0.31, 95% CI -0.31 to 0.94; 40 participants; Cohen
1978, oral decongestant) (SMD 0.36, 95% CI -0.19 to 0.91; 52
participants; Taverner 1999, oral decongestant).
1.1.6 Four hours after dosing
Akerlund 1989 and Cohen 1978 also reported on the effective-
ness of a nasal decongestant compared to placebo four hours after
dosing. Akerlund 1989 used a topical decongestant and Cohen
1978 used an oral decongestant. We were unable to pool results
because we excluded Cohen 1978 from all meta-analyses and both
studies reported different outcome measures (mean and mean dif-
ference (MD)). Neither Akerlund 1989 (SMD 0.31, 95% CI -
0.17 to 0.79; 106 participants; topical decongestant), nor Cohen
1978 (SMD 0.40, 95% CI -0.23 to 1.02; 40 participants; oral
decongestant) showed a statistically significant difference between
the treatment and placebo groups. Furthermore, for both studies
the SMD corresponded to a small clinical effect.
1.1.7 Other
Akerlund 1989, who used a topical decongestant, also reported
on the effectiveness of a single dose of a nasal decongestant seven
hours after dosing. The difference between treatment and placebo
group participants was not statistically significant (SMD 0.10,
95% CI -0.37 to 0.58; 106 participants; Akerlund 1989, topical
decongestant).
Gronborg 1983 is a single-dose study that used an oral decon-
gestant. Gronborg 1983 used a cross-over design and, therefore,
these results were not included in the meta-analyses. Gronborg
1983 reported that during the two to 10 hours observation period
after dosing the mean score for subjective nasal congestion was
better for the treatment group compared to placebo (P < 0.01; 30
participants).
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Results reported by Ferguson 1997 (oral decongestant) were not
included in themeta-analyses because insufficient details were pro-
vided to standardise the results, and it was not clear whenNARwas
measured. Ferguson 1997 reported that the NAR was improved
in the treatment group (P < 0.0001) but not in the control group
(P = 0.98). This study was based on 82 participants.
1.2. Multi-dose decongestant versus placebo
1.2.1 Oral and topical decongestants combined
Subjective symptom scoreswere reported by fivemulti-dose studies
(Bye 1980; Eccles 2005; Eccles 2008; Latte 2007; Sperber 1989).
Only Eccles 2008 used a topical decongestant. Latte 2007 and
Eccles 2005 reported the effectiveness about three hours after the
last dose. Time since the last dose was not clear in Bye 1980,
Eccles 2008 and Sperber 1989.We assumed that overall subjective
symptom scores were measured about three hours after the last
dose because other multi-dose studies also used this timeframe.
We were able to pool results for Eccles 2008 and Sperber 1989
(topical and oral decongestant respectively). These studies pro-
vided a mean score for subjective nasal congestion and the pooled
SMD was statistically significant and in favour of the treatment
group (SMD 0.49, 95% CI 0.07 to 0.92; 94 participants; two
studies; Analysis 1.1). However, a SMD of 0.49 corresponds to a
small clinical effect.
The difference between studies that used oral or topical deconges-
tants was not significant (P = 0.49).
There was no major statistical heterogeneity as confirmed by an I²
statistic of 0%. Nevertheless, we used a random-effects model and
this did not change our results. We judged the level of evidence
to be of low quality because the pooled result was based on only
two studies (imprecision) and there was possible risk of bias due
to unclear reporting.
1.2.2 Oral decongestants
Sperber 1989 was the only study that reported a mean score and
Latte 2007 was the only study that reported the MD. Therefore
we were unable to pool these results. In both studies, the differ-
ence between subjective congestion in the treatment versus placebo
groups was not statistically significant (SMD 0.28, 95% CI -0.47
to 1.02; 33 participants; Sperber 1989, oral decongestant) (SMD
0.15, 95% CI -0.12 to 0.42; 212 participants; Latte 2007, oral
decongestant).
Bye 1980 and Eccles 2005 were not included in the meta-anal-
yses because insufficient details were provided to standardise re-
sults. Bye 1980 (140 participants) reported that there was a statis-
tically significant improvement for subjective nasal congestion in
the treatment group at the end of day one. However, no results for
subjective nasal congestion were provided on days two and three
and it was unclear if subjective nasal congestion in the treatment
group was compared to the control group. Eccles 2005 (238 par-
ticipants) reported no statistically significant difference between
treatment and placebo for the AUC of the VAS between 0 and 3
hours (P = 0.79) and between 0 and 4 hours (P = 0.75) after the
last dose. Only over the three-day period was there a statistically
significant improvement for the mean difference in nasal conges-
tion score for treatment compared to placebo.
1.2.3 Topical decongestants
Only Eccles 2008 used a topical decongestant. In this study the
difference between treatment and placebo was statistically signif-
icant and the SMD of 0.59 corresponded to a moderate clinical
effect (SMD 0.59, 95% CI 0.08 to 1.11; 61 participants; Eccles
2008, topical decongestant).
1.3. All doses of decongestants versus placebo
1.3.1 Oral and topical decongestants combined
Four single-dose studies (Cohen 1978; Eccles 2005; Latte 2004;
Taverner 1999) and five multi-dose studies (Bye 1980; Eccles
2005; Eccles 2008; Latte 2007; Sperber 1989) reported on subjec-
tive symptoms scores. All studies used an oral decongestant except
Eccles 2008, which used a topical decongestant. However, pooling
was possible for three studies only (Eccles 2008; Sperber 1989;
Taverner 1999).
These three studies reported a decline in themean subjective symp-
tom score for nasal congestion, and the pooled effect was statisti-
cally significant (SMD 0.44, 95% CI 0.11 to 0.78; 146 partici-
pants; three studies; Analysis 2.1). However, a SMD of 0.44 cor-
responds to a small effect.
Only Eccles 2008 used a topical decongestant; Sperber 1989 and
Taverner 1999 used oral decongestants. The difference between
studies that used oral or topical decongestants was not significant
(P = 0.49).
There was no major statistical heterogeneity as confirmed by an
I² statistic of 0%. As such, using a random-effects model did not
change our results. We judged the evidence to be of moderate
quality due to possible risk of bias.
1.3.2 Oral decongestants
When only studies that used an oral decongestant were considered
(Sperber 1989; Taverner 1999), the difference between treatment
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and placebo was no longer statistically significant (SMD 0.33,
95% CI -0.11 to 0.77; 85 participants; two studies; Analysis 2.1).
Latte 2004 and Latte 2007 reported the AUC for subjective nasal
congestion; the pooled effect was very small and not statistically
significant (SMD 0.11, 95% CI -0.14 to 0.35; 260 participants;
two studies; Analysis 2.1).
There was no major statistical heterogeneity as confirmed by an
I² statistic of 0% for both the mean nasal congestion and the
AUC. Using a random-effects model did not change our results.
We judged the evidence to be of low quality because of possible
risk of bias due to unclear reporting and imprecision.
None of the studies included in the meta-analyses for the pri-
mary outcome measure reported intention-to-treat (ITT) analy-
ses (Eccles 2008; Latte 2004; Latte 2007; Sperber 1989; Taverner
1999). Only in Eccles 2008 was the mean subjective score for
nasal congestion significantly better for the treatment group com-
pared to placebo. Eccles 2008 randomised 61 participants but five
people were not dosed or analysed; reasons for exclusion were not
provided. In the other studies, participants were excluded from
analysis because they were unable to perform the rhinomanome-
try (Latte 2004), had incomplete data (Latte 2007), were infected
with awild type rhinovirus, withdrew for personal reasons (Sperber
1989), or were unable to complete the study (Taverner 1999).
1.3.3 Topical decongestants
Only Eccles 2008 used a topical decongestant. The difference
between treatment and placebo was statistically significant and the
SMD of 0.59 corresponded to a moderate clinical effect (SMD
0.59, 95% CI 0.08 to 1.11; 61 participants).
2. Overall patient well-being score (self-reported)
The included trials did not report this outcome.
Secondary outcomes
1. Objective measures of nasal airway resistance (NAR)
1.1. Single-dose decongestant versus placebo
Objective measures of NAR were tested between 15 minutes and
10 hours after dosing. Similar to subjective measures of NAR, we
were unable to pool results. Therefore, we report results for all
time points in more detail for each study.
1.1.1 15 minutes after dosing
Only Cohen 1978 objectively measured the immediate effect of
a nasal decongestant versus placebo 15 minutes after administra-
tion. This was assessed by the mean difference in NAR. The esti-
mated SMD was small and the difference between the treatment
and placebo groups was not statistically significant (SMD 0.42,
95% CI -0.21 to 1.04; 40 participants). This study used an oral
decongestant.
1.1.2 30 minutes after dosing
Two studies objectively assessed the effectiveness of oral deconges-
tant treatment after 30 minutes (Cohen 1978; Taverner 1999). In
both studies, the estimated SMD between treatment and placebo
groups was not statistically significant (SMD 0.21 95% CI -0.41
to 0.83; 40 participants; Cohen 1978), (SMD 0.08 95% CI -0.49
to 0.64; 48 participants; Taverner 1999).
1.1.3 One hour after dosing
Five studies objectively measured the effectiveness of a nasal de-
congestant one hour after dosing (Akerlund 1989; Cohen 1978;
Eccles 2006; Eccles 2008; Taverner 1999). Of these, two used
a topical decongestant (Akerlund 1989; Eccles 2008), and three
used an oral decongestant (Cohen 1978; Eccles 2006; Eccles 2008;
Taverner 1999). The reported outcome measurements varied con-
siderably; mean scores and mean differences of NAR as well as
mean scores and least square mean scores of NAC were reported.
Therefore, we were unable to pool results. Akerlund 1989, Eccles
2006 and Eccles 2008 showed that the difference between treat-
ment and placebo was statistically significant and corresponded to
a moderate to large effect (SMD 0.65, 95% CI 0.14 to 1.15; 102
participants; Akerlund 1989, topical decongestant), (SMD 0.58,
95% CI 0.26 to 0.90; 153 participants; Eccles 2006, oral decon-
gestant), (SMD1.06, 95%CI 0.52 to 1.59; 61 participants; Eccles
2008, topical decongestant). In contrast, the estimated SMD be-
tween treatment and placebo was not statistically significant in
Cohen 1978 and Taverner 1999 (SMD 0.54 95% CI -0.10 to
1.17; 40 participants; Cohen 1978, oral decongestant), (SMD
0.43 95% CI -0.14 to 1.00; 48 participants; Taverner 1999, oral
decongestant).
1.1.4 Two hours after dosing
Three studies reported the effectiveness of oral nasal deconges-
tant compared to placebo two hours after treatment (Cohen 1978;
Latte 2004; Taverner 1999). Again, we were unable to pool results.
Latte 2004 showed a large and statistically significant difference
between treatment and placebo groups for the AUC from baseline
to two hours (SMD 0.88, 95% CI 0.28 to 1.47; 48 participants;
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Latte 2004, oral decongestant). However, the estimated SMD be-
tween treatment and placebo was not statistically significant in
Cohen 1978 and Taverner 1999 (SMD 0.27, 95% CI -0.35 to
0.89; 40 participants; Cohen 1978, oral decongestant), (SMD
0.17, 95% CI -0.40 to 0.74; 48 participants; Taverner 1999, oral
decongestant).
1.1.5 Three hours after dosing
Four studies reported on the effectiveness of a nasal decongestant
compared to placebo three hours after dosing (Akerlund 1989;
Cohen 1978; Latte 2007; Taverner 1999). Only Akerlund 1989
used a topical decongestant and showed a large and statistically sig-
nificant difference for meanNAR between treatment and placebo,
in favour of the treatment group (SMD 0.74, 95% CI 0.23 to
1.25; 102 participants). None of the other studies showed a statis-
tically significant difference between treatment and placebo (SMD
0.28, 95% CI -0.34 to 0.90; 40 participants; Cohen 1978, oral
decongestant), (SMD 0.20, 95% CI -0.07 to 0.47; 212 partici-
pants; Latte 2007, oral decongestant), (SMD -0.30 95% CI -0.87
to 0.27; 48 participants; Taverner 1999, oral decongestant).
1.1.6 Four hours after dosing
Three studies reported on the effectiveness of an oral nasal decon-
gestant compared to placebo four hours after dosing (Cohen 1978;
Eccles 2005; Eccles 2006). Cohen 1978 was excluded from all
meta-analyses; all three studies reported different outcome mea-
sures (mean, MD and AUC) so we were unable to pool results.
Only Eccles 2006 showed that the AUC of the NAC measure-
ments between baseline and four hours was significantly better for
the treatment group compared to the placebo group (SMD 0.54,
95% CI 0.21 to 0.86; 153 participants). The SMD corresponded
to a moderate clinical effect. Cohen 1978 (SMD 0.40, 95% CI -
0.23 to 1.02; 40 participants) and Eccles 2005 (SMD 0.19, 95%
CI -0.06 to 0.45; 236 participants) did not report a statistically
significant difference between the treatment and placebo group.
1.1.6 Other
Only Akerlund 1989 reported the effectiveness of a single dose of
a nasal decongestant up to seven hours after dosing. This study
used a topical decongestant and showed a small difference between
treatment and placebo that was not statistically significant (SMD
0.36, 95% CI -0.14 to 0.86; 102 participants).
Gronborg 1983, a single-dose oral decongestant study that used
a cross-over design, involved 30 participants. It was not included
in the meta-analyses. Gronborg 1983 found that NAR worsened
in the placebo group whereas it improved in the treatment group;
this difference was statistically significant (P < 0.02).
1.2. Multi-dose decongestant versus placebo
1.2.1 Oral and topical decongestants combined
Four multi-dose studies reported objective measurements of nasal
congestion (Eccles 2005; Eccles 2008; Jawad 1998; Latte 2007).
All studies except Eccles 2008 used an oral decongestant. Objec-
tive measurements of nasal congestion were represented as mean
NAR (Eccles 2005), the AUC for NAR (Latte 2007), the mean
NAC (Jawad 1998), and the least square mean of NAC (Eccles
2008). As all four studies reported different outcome measures, we
were unable to pool results. Jawad 1998 and Latte 2007 reported
the effectiveness of a nasal decongestant three hours after the last
dose, and Eccles 2005 measured this four hours after the last dose.
Timing since last dose was not clear in Eccles 2008. Therefore,
we report the effectiveness of multi-dose decongestants assessed
approximately three hours after the last dose.
1.2.2 Oral decongestants
In Eccles 2005 (SMD 0.11, 95% CI -0.14 to 0.37; 230 partici-
pants), Jawad 1998 (SMD 0.23, 95% CI -0.39 to 0.86; 40 partic-
ipants) and Latte 2007 (SMD 0.10, 95% CI -0.17 to 0.37; 212
participants) the effect of multiple doses of oral decongestants on
objective measurements of nasal congestion was not statistically
significant.
1.2.3 Topical decongestants
Of the four studies that reported objective measurements of nasal
congestion, Eccles 2008 was the only study that used a topical
decongestant and showed a statistically significant effect of mul-
tiple doses of nasal decongestant on objective measurements of
nasal congestion: in this study expressed as the least square mean
of NAC (SMD 0.89, 95% CI 0.36 to 1.41; 61 participants). The
SMD of 0.89 corresponded to a significant clinical effect.
1.3. All doses of decongestants versus placebo
1.3.1 Oral and topical decongestants combined
In total, four single-dose (Akerlund 1989; Cohen 1978; Latte
2004; Taverner 1999) and four multi-dose studies (Eccles 2005;
Eccles 2008; Jawad 1998; Latte 2007) reported on objective mea-
sures of NAR. Only one single-dose study (Akerlund 1989) and
one multi-dose study (Eccles 2008) used a topical decongestant.
Pooling was possible for four studies only (Analysis 2.3): two sin-
gle-dose studies (Akerlund 1989; Latte 2004) and two multi-dose
studies (Eccles 2005; Latte 2007).
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Two studies reported a reducedmeanNARcomparedwith placebo
(Akerlund 1989; Eccles 2005), but the reduction was small and
not statistically significant (SMD 0.39, 95% CI -0.22 to 0.99;
332 participants; two studies; Analysis 2.3). Akerlund 1989 used
a topical decongestant and Eccles 2005 used an oral deconges-
tant. The difference between studies that used an oral or topical
decongestants was statistically significant (P = 0.03); the effect of
treatment was significant in Akerlund 1989 (topical decongestant)
and not significant in Eccles 2005 (oral decongestant). However,
each subgroup only included one study.
There seemed to be considerable heterogeneity as shown by an I²
statistic of 78%. The differentmeasurement instruments probably
explain the high heterogeneity; Akerlund 1989 measured NAR
with anterior rhinomanometry in the left nostril whereas Eccles
2005 measuredNARwith posterior rhinomanometry.We applied
a random-effects model because this changed the interpretation of
the results from statistically significant to not statistically signifi-
cant.
1.3.2. Oral decongestants
Latte 2004 and Latte 2007 used an oral decongestant and reported
the AUC for NAR. Their pooled effect was not statistically signif-
icant (SMD 0.44, 95% CI -0.32 to 1.20; 260 participants; two
studies; Analysis 2.3).
For the pooled effect of the AUC for NAR, there seemed to be
considerable heterogeneity as shown by an I² statistic of 82%.
Interestingly, Latte 2004 and Latte 2007 were conducted at the
same institution with the same research team. Both assessed the
effectiveness of pseudoephedrine in a similar population. The only
differences between the studies were the dosage and the measure-
ment instrument; Latte 2004 was a single-dose study and NAR
was measured with acoustic rhinomanometry, whereas Latte 2007
was a multi-dose study, with NAR being measured by posterior
rhinomanometry.We applied a random-effects model because this
changed the interpretation of the results from statistically signifi-
cant to not statistically significant.
1.3.3 Topical decongestant
Only Akerlund 1989 and Eccles 2008 used a topical deconges-
tant. Akerlund 1989 reported themeanNARwhereas Eccles 2008
reported the least square mean of NAC. Therefore, we were un-
able to pool results. Both studies showed a large and statistically
significant difference between treatment and placebo, in favour
of the treatment group (SMD 0.74, 95% CI 0.23 to 1.25; 102
participants; Akerlund 1989), (SMD 0.89, 95% CI 0.36 to 1.41;
61 participants; Eccles 2008).
2. Adverse events
2.1. Single-dose decongestant versus placebo
Two single-dose trials reported adverse events (Gronborg 1983;
Taverner 1999); both used an oral decongestant. Taverner 1999
reported no adverse events in either the treatment or the placebo
group. Results from Gronborg 1983 were not included in the
meta-analysis because this study used a cross-over study design and
several events per patient were reported. Overall, 32 and 21 events
were reported in the treatment and placebo groups respectively;
this was not statistically significant.
2.2. Multi-dose decongestant versus placebo
2.2.1 Oral and topical decongestants combined
Adverse events were reported by sevenmulti-dose studies (Analysis
1.2) (Bye 1980; Eccles 2005; Eccles 2006; Eccles 2008; Eccles
2014; Latte 2007; Sperber 1989). All studies except Eccles 2008
used an oral decongestant. With the exception of Eccles 2014,
all studies reported specific adverse events. However, the adverse
events differed among studies and ranged from vomiting and dry
mouth, to lethargy, dizziness, pain and mouth ulcers. In Latte
2007, adverse events were not clearly described in the original
paper, but these were included in the Cochrane Review by the
same authors (Taverner 2007); therefore, we used these numbers
in our review as well.
We only reported the specific type of adverse event if this was
reported by more than one study.
All adverse events
Seven studies reported the total number of participants with ad-
verse events (Bye 1980; Eccles 2005; Eccles 2006; Eccles 2008;
Eccles 2014; Latte 2007; Sperber 1989). In both treatment and
placebo arms, 13% of participants reported an adverse event. The
chance of having an adverse event was slightly lower for treatment
group participants. However, the difference with the placebo was
not statistically significant (OR 0.98, 95% CI 0.68 to 1.40; 1195
participants; seven studies; Analysis 1.2).
The difference between studies that used an oral or topical decon-
gestant was not significant (P = 0.68).
For the pooled effect of all adverse events there was no clear het-
erogeneity given the I² statistic of 0%. We used a random-effects
model throughout all analyses for adverse events and this did not
change the interpretation of the results.
We judged the evidence for all adverse events to be of low quality
because of possible risk of bias due to unclear reporting and lack
of precision (wide confidence interval).
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Insomnia or difficulty sleeping
Four studies reported the incidence of insomnia or difficulty sleep-
ing (Bye 1980; Eccles 2005; Latte 2007; Sperber 1989); all used
an oral decongestant. These results are reported in 2.2.2 Oral de-
congestants.
Headache
Headache was reported by three studies (Eccles 2005; Eccles 2008;
Latte 2007). Neither individual studies nor the pooled estimate
showed a statistically significant difference between treatment and
placebo group participants (OR 0.89, 95% CI 0.23 to 3.37; 511
participants; three studies; Analysis 1.4). Only Eccles 2008 used
a topical decongestant.
The difference between studies that used an oral or topical decon-
gestant was not significant (P = 0.14).
There seemed to be moderate heterogeneity given the I² statistic
of 34%. We used a random-effects model and this did not change
the interpretation or the results.
2.2.2 Oral decongestants
All adverse events
Six studies that used an oral decongestant reported total numbers
of participants with adverse events (Bye 1980; Eccles 2005; Eccles
2006; Eccles 2014; Latte 2007; Sperber 1989). The difference
with placebo was not statistically significant (OR 0.95, 95% CI
0.65 to 1.39; 1134 participants; six studies; Analysis 1.2).
For the pooled effect of all adverse events there was no clear het-
erogeneity given the I² statistic of 0%. We used a random-effects
model for all analyses of adverse events; this did not change the
interpretation or the results.We judged the evidence for all adverse
events to be of moderate quality because of possible risk of bias
due to unclear reporting.
Insomnia or difficulty sleeping
Four studies reported the incidence of insomnia or difficulty sleep-
ing (Bye 1980; Eccles 2005; Latte 2007; Sperber 1989); all used an
oral decongestant. Two studies found a significantly lower risk in
the treatment group compared to placebo (Bye 1980; Latte 2007),
but the pooled estimate was not statistically significant (OR 0.39,
95%CI 0.09 to 1.62; 623 participants; four studies; Analysis 1.3).
There seemed to be moderate heterogeneity given the I² statistic
of 50%. We used a random-effects model and this changed the
effect from statistically significant to not significant.
Headache
Headache was reported by two studies that used an oral decon-
gestant (Eccles 2005; Latte 2007). Neither the individual studies
nor the pooled estimate showed a statistically significant difference
between treatment and placebo groups (OR 0.58, 95% CI 0.19
to 1.84; 450 participants; two studies; Analysis 1.4).
There was no clear heterogeneity given the I² statistic of 0%. We
used a random-effects model and this did not change the inter-
pretation or the results.
2.2.3 Topical decongestants
All adverse events
Only Eccles2008 used a topical decongestant and reported adverse
events. In this study the difference between treatment and placebo
was not statistically significant (OR 1.23, 95% CI 0.39 to 3.88;
61 participants).
Insomnia or difficulty sleeping
None of the studies that used a topical decongestant reported
insomnia or difficulty sleeping.
Headache
Only Eccles 2008 used a topical decongestant and reported
headache as an adverse event. In this study the difference between
treatment and placebo groups was not statistically significant (OR
4.00, 95% CI 0.42 to 38.07; 61 participants).
2.3. All doses of decongestants versus placebo
Two single-dose studies reported adverse events associated with
oral decongestants (Gronborg 1983; Taverner 1999). Taverner
1999 reported no events and Gronborg 1983 was excluded from
meta-analyses because it was a cross-over study. Therefore, com-
bining single-dose and multi-dose studies resulted in the same re-
sults for multi-dose adverse events (Analysis 1.2).
3. Complications
None of the included studies reported this outcome.
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4. Time to full recovery
4.1. Single-dose decongestant versus placebo
The included single-dose trials did not report this outcome.
4.2. Multi-dose decongestant versus placebo
Only one multi-dose study reported the time to full recovery (
Reinecke 2005, 247 participants). Reinecke 2005 used a topical
decongestant and showed that the mean time until full recovery
was better for the treatment group (four days) compared to the
placebo group (six days; P = 0.001).
5. Time to return to school/work
The included trials did not report this outcome.
Subgroup analyses
1. Single-dose decongestant versus placebo
1.1 Children versus adults
We planned to compare studies in children aged up to 12 years
compared with those aged over 12 years. However, none of the
single-dose studies included children sowewere unable to perform
this subgroup analysis.
1.2 Oral versus topical
The other subgroup analysis, as specified a priori, was to com-
pare oral versus nasal decongestants. Since we were unable to pool
studies we could not perform this subgroup analysis. However,
for each comparison in this review we report whether an oral or
topical decongestant was used.
2. Multi-dose decongestant versus placebo
2.1 Children versus adults
We planned to compare studies in children aged up to 12 years
compared with those aged over 12 years. However, none of the
multi-dose studies included children. Reinecke 2005 included
people aged 12 years and above so excluded children.
2.2 Oral versus topical
For themulti-dose studies, wewere only able to pool results for the
primary outcome, subjective symptom scores for nasal congestion
(three studies), and adverse events (seven studies). Therefore, as-
sessing the difference between oral versus topical nasal deconges-
tants on subjective symptom scores for nasal congestion involved
two studies that used anoral decongestant (Sperber 1989;Taverner
1999), and one that used a topical decongestant (Eccles 2008).
The difference between studies that used an oral decongestant and
the study that used a topical decongestant was not statistically sig-
nificant (P = 0.45). Also for adverse events, there was only one
study that used a topical decongestant (Eccles 2008); all others
used an oral decongestant (Bye 1980; Eccles 2005; Eccles 2006;
Eccles 2014; Latte 2007; Sperber 1989). The difference between
the pooled result for the oral decongestant versus the only study
on the topical decongestant was not statistically significant (P =
0.68).
3. All doses of decongestants versus placebo
3.1 Children versus adults
We planned to compare studies in children aged up to 12 years
compared with those aged over 12 years. However, none of the
studies included children.
3.2 Oral versus topical
We were able to assess the impact of oral versus topical decon-
gestants only for outcomes where we could pool results and there
were both single and multi-dose studies available. This was only
possible for the primary outcome, subjective symptom scores, and
the secondary outcome, objective measures of NAR.
For the primary outcome of subjective symptom scores, three stud-
ies reported the mean score (Eccles 2008; Sperber 1989; Taverner
1999), and two studies reported anAUC (Latte 2004; Latte 2007).
Since pooling of these two outcome measures was not appropriate
we discuss both separately. For studies that reported the mean sub-
jective symptom score, we compared the pooled effect of the two
studies that used an oral decongestant (Sperber 1989; Taverner
1999) with the results of one study that used a topical deconges-
tant (Eccles 2008). The difference between the two was not statis-
tically significant (P = 0.45). For the two studies that used AUC as
an outcome we were unable to assess differences between oral and
topical decongestants because both used an oral decongestant.
Similar to the subjective symptom scores, objective measures of
NAR were reported as the mean (Akerlund 1989; Eccles 2005),
and the AUC (Latte 2004; Latte 2007). Since Latte 2004 and Latte
2007 both used an oral decongestant we were only able to assess
the difference between Akerlund 1989 and Eccles 2005, which
used topical and oral decongestants respectively. The difference
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between oral and topical decongestants was statistically significant
(P = 0.03). However, each subgroup only included one study.
As for multi-dose decongestants we indicated if results were based
on studies using an oral or topical decongestant. These results are
reported in more detail above.
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Should multiple doses of decongestant in monotherapy be used for the common cold in adults?
Patient or population: adult pat ients with the common cold
Settings: common cold centres, universit ies and hospitals
Intervention: mult i-dose decongestant in monotherapy, oral and topical decongestants combined
Comparison: placebo
M easure of effect: we transformed results f rom all studies to ensure that higher scores represent better funct ioning. We standardised results using the standardised mean
dif ferences (SMD). As such dif ferences are expressed in standardised units. As a rough guide, a SMD of 0.2 to 0.49 represents a small, 0.5 to 0.79 a moderate and ≥ 0.8 a
large clinical ef fect
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with multi-dose
decongestant
Primary outcome: sub-
ject ive symptom score
(mean) - 3 hours af ter
dosing
The unstandardised
mean subject ive symp-
tom score ranged f rom
-7 to -35.79
Subject ive nasal con-
gest ion was 0.49 stan-
dard units better in the
treatment group (95%
CI 0.07 to 0.92; P value
0.02)
- 94
(2 RCTs)
⊕⊕©©
LOW 12
Xylometazoline (Eccles
2008); pseu-
doephedrine (Sperber
1989)
Primary outcome: sub-
ject ive symptom score
(mean) - 3 hours af ter
dosing
Oral
- - - 33
(1 RCT)
- Insuf f icient data to pool
results
Pseudoephedrine
(Sperber 1989)
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Primary outcome: sub-
ject ive symptom score
(mean) - 3 hours af ter
dosing
Topical
- - - 61
(1 RCT)
- Insuf f icient data to pool
results
Xylometazoline (Eccles
2008)
Primary outcome: over-
all pat ient well-being
- - - (0 studies) - Not reported
Secondary outcome: all
adverse events
Study populat ion OR 0.98
(0.68 to 1.40)
1195
(7 RCTs)
⊕⊕©©
LOW 3
Pseudoephedrine (Bye
1980; Eccles 2005;
Eccles 2006; Eccles
2014; Sperber 1989);
triprolidine (Bye 1980);
xylometazoline (Eccles
2008)
126 per 1000 124 per 1000
(89 to 168)
Secondary outcome: all
adverse events
Oral
Study populat ion OR 0.95
(0.65 to 1.39)
1134
(6 RCTs)
⊕⊕©©
LOW 4
Pseudoephedrine (Bye
1980; Eccles 2005;
Eccles 2006; Eccles
2014; Sperber 1989);
triprolidine (Bye 1980)
121 per 1000 115 per 1000
(82 to 160)
Secondary outcome: all
adverse events
Topical
Study populat ion - 61
(1 RCT)
- Insuf f icient data to pool
results
Xylometazoline (Eccles
2008)- -
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; OR: odds rat io; RCT: randomised controlled trial
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent2
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Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded because of possible risk of bias; random sequence generat ion and allocat ion concealment was not clear in
both studies.
2Downgraded because data came f rom only two studies.
3Downgraded because three studies had unclear risk of bias on f ive out of seven domains (Eccles 2008; Latte 2007; Sperber
1989), and the est imate had a wide conf idence interval (imprecision).
4Downgraded because two studies had unclear risk of bias on f ive out of seven domains (Latte 2007; Sperber 1989), and the
est imate had a wide conf idence interval (imprecision).
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Should a decongestant (any dose) in monotherapy be used for the common cold in adults?
Patient or population: adult pat ients with the common cold
Settings: common cold centres, universit ies and hospitals
Intervention: single-dose or mult i-dose decongestant in monotherapy, oral and topical decongestants combined
Comparison: placebo
M easure of effect: we transformed results f rom all studies to ensure that higher scores represent better funct ioning. We standardised results using the standardised mean
dif ferences (SMD). As such dif ferences are expressed in standardised units. As a rough guide, a SMD of 0.2 to 0.49 represents a small, 0.5 to 0.79 a moderate and ≥ 0.8 a
large clinical ef fect
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with all doses of
decongestants
Primary outcome: sub-
ject ive symptom score
(mean) - 3 hours af ter
dosing
The unstandardised
mean subject ive symp-
tom score ranged f rom
-2.54 to -35.79
Subject ive nasal con-
gest ion was 0.44 stan-
dard units better in the
treatment group (95%
CI 0.11 to 0.78; P value
0.01)
- 146
(3 RCTs)
⊕⊕⊕©
MODERATE 1
Pseu-
doephedrine (Sperber
1989; Taverner 1999);
xylometazoline (Eccles
2008)
Primary outcome: sub-
ject ive symptom score
(mean) - 3 hours af ter
dosing
Oral
The unstandardised
mean subject ive symp-
tom score ranged f rom
-2.54 to -7
Subject ive nasal con-
gest ion was 0.33 stan-
dard units better in the
treatment group (95%
CI -0.11 to 0.77; P value
0.14)
- 85
(2 RCTs)
⊕⊕©©
LOW 23
Pseudoephedrine (
Sperber 1989; Taverner
1999)
Primary outcome: sub-
ject ive symptom score
(mean) - 3 hours af ter
dosing
Topical
- - - 61
(1 RCT)
- Insuf f icient data to pool
results
Xylometazoline (Eccles
2008)
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Primary outcome: sub-
ject ive symptom score
(AUC) - 3 hours af ter
dosing
Oral
The unstandardised
mean AUC for the sub-
ject ive symptom score
ranged f rom 22 to -77.
45
Subject ive nasal con-
gest ion was 0.11 stan-
dard units better in the
treatment group (95%
CI -0.14 to 0.35; P value
0.39)
- 260
(2 RCTs)
⊕⊕©©
LOW 34
None of the included
studies that used a top-
ical decongestant re-
ported the AUC for sub-
ject ive symptoms of
congest ion
Pseudoephedrine (
Latte 2004; Latte 2007)
Primary outcome:
overall pat ient well-be-
ing
- - - (0 studies) - Not reported
Secondary outcome:
All adverse events
Only 2 single-dose studies reported adverse events. One study reported
no events (Taverner 1999, pseudoephedrine) and the other was excluded
f rom meta-analyses as this was a cross-over study (Gronborg 1983,
norephedrine). Combining single-dose and mult i-dose studies would not
change the results of the mult i-dose analyses
- - -
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; AUC: area under the curve; NAR: nasal airway resistance; RCT: randomised controlled trial
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
¹Downgraded because two studies had unclear risk of bias on f ive out of seven domains (Eccles 2008; Sperber 1989).
²Downgraded because one study had unclear risk of bias on f ive out of seven domains (Sperber 1989).
³Downgraded because data came f rom only two studies.
Downgraded because one study had unclear risk of bias on f ive out of seven domains (Latte 2007).
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D I S C U S S I O N
Summary of main results
We compared the effectiveness of nasal decongestants adminis-
tered as single and multiple doses to treat nasal congestion in peo-
ple with the common cold. We included 15 trials and analyses
were based on a total of 1838 participants. Nine studies used pseu-
doephedrine and three used oxymetazoline. Other decongestants
included phenylpropanolamine, norephedrine and xylometazo-
line. The studies that used phenylpropanolamine or norephedrine
were excluded from meta-analyses because this drug is no longer
available in most countries (FDA 2000). There were large differ-
ences in reported outcomes. Reporting of study methods was lim-
ited inmost studies. Therefore, pooling was only possible for a few
studies. All studies, except one, included adult participants only
(aged 18 years and over). Reinecke 2005 included younger people
(aged up to 12 years) but did not provide details on the mean age
of participants. As such, the results of this review are applicable to
adults only.
We were unable to draw conclusions on the effectiveness of single-
dose decongestants because pooling was not possible due to the
large diversity in measuring and reporting symptoms of conges-
tion. For other outcome measures, such as overall patient well-
being and time to recovery, either no data or insufficient data were
available.
For multiple doses of decongestant, meta-analysis was possible for
subjective measures of congestion only (measured approximately
three hours after the last dose). Subjective measures of congestion
were significantly better for treatment group participants com-
pared to placebo group participants. However, the clinical effect
was small, and this result was based on two studies only (one top-
ical and one oral decongestant) and involved a total of 88 partici-
pants.
Hence, for multiple doses of a nasal decongestant it seems that
there is a small beneficial effect on nasal congestionwhenmeasured
subjectively. Although subjective measures of nasal congestion are
probably the most relevant outcomes, since nasal decongestants
are used for symptomatic relief only, it is not clear if this small
effect is clinically relevant and sufficient to justify widespread use
of decongestants (Taverner 2007).
There were insufficient data to estimate differences in the effi-
cacy of oral versus topical decongestants. Adverse events were re-
ported in nine studies and the risk of adverse events in treatment
group participants was not significantly different from people in
the placebo group. It seems that short-term use of nasal deconges-
tants in adults with the common cold can be considered safe.
Overall completeness and applicability of
evidence
We recognise that there were few included studies. In addition,
because these studies were very heterogeneous in their approach to
outcome measures, the number of studies that could be pooled for
each outcome was even smaller, with most subgroup analyses only
containing two studies. Hence, the generalisability of our results
is very limited.
With respect to adverse events it was surprising to note that none
of the included multi-dose studies investigated the problem of
tachyphylaxis or rhinitis medicamentosa. This could be due to the
limited follow-up in most studies (between one and 10 days). Fur-
thermore, the side effects profile of oral versus topical deconges-
tants might differ; one might expect more systemic and delayed
side effects with oral preparations. We were unable to assess this
aspect because only one study that used a topical decongestant
reported adverse effects.
Twelve studies used subjective measures as outcomes, which are
probably the most relevant outcomes to clinical applicability, be-
cause nasal decongestants are used for symptomatic relief. In ad-
dition, all studies, except one, included participants with commu-
nity-acquired common cold.
The results are only applicable to an adult population because
none of the studies included children aged 12 years or younger.
Another concern about the applicability of the current evidence
relates to the use of pseudoephedrine. Nine studies tested the ef-
fectiveness of pseudoephedrine; however, this has not been avail-
able since 2005 as an over-the-counter decongestant because it
can be used to make methamphetamine (FDA 2005). Currently,
pseudoephedrine is being replaced by phenylephrine as a way to
control methamphetamine abuse. Despite phenylephrine being a
common decongestant that is available over-the-counter, none of
the studies in this review evaluated its effectiveness.
Quality of the evidence
For most outcomes we downgraded the quality of evidence to
moderate or low due to the limited data available or poor ’Risk
of bias’ assessments. We included 15 studies, with a total of 1838
participants, but pooling was often not possible. When pooling
was possible, results were often only based on two studies. All
studies except one included adult participants and so the findings
of our review cannot be generalised to children. We recognise that
over half of the included studies were published before 2000, and
that many of the studies do not provide sufficient methodological
information to exclude risk of bias. Hence, for most studies, risk
of bias is unclear.
Potential biases in the review process
Given the small number of included studies, it is possible that
we did not find all relevant trials. Hence, publication bias can-
not be definitively ruled out, which may lead to overestimation
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of the treatment effect. For example, we found four studies that
were relevant for this review, but no results were available. Two
are completed trials with no published results (NCT00452270;
NCT01062360), and a third, although originally registered in
2007, is stated to be ongoing (EUCTR2006-006690-25-GB).
The fourth study is also ongoing; it started in 2012, but the esti-
mated completion date recently changed from April 2015 to May
2016 (NCT01744106).
This review was conducted as outlined in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011).We searched
several databases and three authors (LD, LG, NM) independently
selected studies and extracted data, thus minimising the risk of
introducing bias during the review process.
Agreements and disagreements with other
studies or reviews
Our results are in line with those of other systematic reviews and
meta-analyses. In a similar, but older, Cochrane Review on nasal
decongestants for the common cold, Taverner 2007 concluded
that nasal decongestants are modestly effective for the short-term
relief of congestion in adults. Two hours after dosing, a signifi-
cant decrease in patient-reported symptoms for treatment versus
placebo was described. Similar to our findings, the effects were
small and although statistically significant, it is not clear if the re-
duction in symptoms is clinically relevant and sufficient to justify
widespread use of decongestants (Taverner 2007).
Several other reviews on nasal decongestants for the common cold
have also been published (e.g. Allan 2014; Arroll 2005; Arroll
2011; Meltzer 2010). Generally, their conclusions were based on
the Cochrane Reviews Taverner 2004 and Taverner 2007, or more
recent studies that were included in this review. Accordingly, the
results and conclusions are similar and in line with this review.
Kollar 2007 investigated the effectiveness of a single 10 mg dose
of phenylephrine compared to placebo. Kollar 2007 showed that
a single oral dose of phenylephrine significantly improved acute
nasal congestion.However, itmust be noted that themeta-analyses
in this review were almost completely based on small unpublished
studies conducted between 1968 and 1975, which were included
in amonograph by theUS Food andDrug Administration (FDA).
According to Eccles 2007, the studies included in the FDA report
were in-house studies provided by representatives of pharmaceu-
tical companies (Eccles 2007).
Another review on xylometazoline (alone and in combination)
concluded that xylometazoline provides fast and effective relief
from nasal congestion (Eccles 2010). However, this review in-
cluded only four studies and did not include a meta-analysis. We
included only one study that used xylometazoline (Eccles 2008).
Hence, we were unable to formulate firm conclusions about the
effectiveness of this medication. Furthermore, it was beyond the
scope of our review to evaluate the effectiveness of different nasal
decongestants individually.
TheCochrane Review on combination drugs for the common cold
(oral antihistamine-decongestant-analgesic combinations) found
that the effect on individual symptoms is small, “probably too
small to be clinically relevant” (De Sutter 2012). The lack of evi-
dence in childrenwas also confirmed by other studies on deconges-
tants alone and combination products (Allan 2014; Arroll 2005;
De Sutter 2012).
In terms of the risk of side effects our resultswere in agreementwith
other reviews and studies; the incidence of side effects with short-
term use of decongestants is low and side effects are mostly mild to
moderate (e.g. insomnia and headache) (Allan 2014; Eccles 2010;
Taverner 2007). Although we did not identify data on the safety of
nasal decongestants in children, there are reports of adverse events
after single use of nasal decongestant. For example, the FDA pub-
lished a warning in 2012 about serious adverse events after inges-
tion of over-the-counter nasal sprays containing oxymetazoline by
children under the age of six years (FDA 2012).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The effectiveness of nasal decongestants in monotherapy is uncer-
tain. There may be a small benefit on the subjective experience
of nasal congestion after multiple doses of a nasal decongestant
(low-quality evidence). However, it is unclear if the small effect is
clinically relevant. Due to the small number of studies that used
a topical nasal decongestant, we were unable to draw conclusions
on the effectiveness of oral versus topical decongestants. The in-
cidence of mostly mild-to-moderate side effects was low. These
results are applicable to adults only. Despite common colds being
equally common in children, there is no evidence available on ei-
ther effectiveness or safety in children.
Implications for research
Given the high consumption of nasal decongestants it was surpris-
ing that so little evidence is available. Questions about the effec-
tiveness and safety in children remain unanswered.However, given
the reports of serious adverse events in young children, further
research in this group does not appear to be warranted or feasible
(FDA 2012). Some questions regarding the effectiveness and safety
of nasal decongestants in adults also remain unanswered. More re-
search is need to investigate the long-term effects of multiple doses
of nasal decongestants on tachyphylaxis or rhinitis medicamentosa
and the differences between oral and topical decongestants need
to be explored.
Wewere unable to compare the effectiveness of different deconges-
tants. For example, pseudoephedrine is often replaced by phenyle-
phrine as a way to control methamphetamine abuse. However,
as a decongestant, phenylephrine may not be as effective (Eccles
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2007). Despite phenylephrine being a common decongestant that
is available over-the-counter, none of the included studies evalu-
ated its effectiveness. Hence, more large-scale, good-quality ran-
domised controlled trials evaluating the effectiveness of several
nasal decongestants are needed.
Furthermore, future research should seek to define aminimal clini-
cally important difference for measures of subjective improvement
in nasal congestion. As this was not available, we used a statisti-
cal approach to interpret our results. For example, a we regarded
a standardised mean difference between 0.2 and 0.49 as a small
effect. However, it remains unclear how this small statistical effect
corresponds to clinical effect.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Akerlund 1989
Methods Randomised, double-blind, placebo-controlled, parallel-group study
Participants N recruited: 106 males undergoing military training
N analysed: 106
- Oxymetazoline (4 groups with different dosages) N = 85
- Placebo N = 21
Age: between 18 and 28 years, mean age 20.1 years
Country: Sweden
Inclusion criteria:
Patients with the common cold
Not more than 2 days duration of symptoms
Exclusion criteria:
Patients with nasal polyps or a pronounced septal deviation
Patients with a history of frequent nasal congestion, sinusitis or allergy
Diagnostic criteria: only patients with objectively obstructed noses, defined as V2 > 35°
and a reproducible initial value (difference in V2 ≤ 6° in 2 consecutive measurements)
was required
Interventions Treatment before study: no medication possibly influencing nasal congestion was al-
lowed
Nasal decongestant dose:
- Group 1: 0.1 mg/mL oxymetazoline, in 0.1 mL dose pipettes, N = 22
- Group 2: 0.25 mg/mL oxymetazoline, in 0.1 mL dose pipettes, N = 21
- Group 3: 0.25 mg/mL oxymetazoline, in 0.2 mL dose pipettes, N = 21
- Group 4: 0.5 mg/mL oxymetazoline, in 0.1 mL dose pipettes, N = 21
- Placebo: 0 mg/mL in 0.1 mL dose pipettes, N = 21
Administration: single dose
Nasal spray: the drug was administered once into each nostril using single-dose pipettes
with the patient’s head inclined backwards
Follow-up: 1 day
Measurements:
Before and 10 min after administration of the drug and then every hour for 7 hours
Changes in nasal airway resistance were measured by anterior rhinomanometry, in the
left nostril
Subjective symptom scores were the patient’s experience of the symptoms of nasal block-
age, secretion, itching, sneezing and coughing, on a 4-point score scale (0 to 3) from
none to severe symptoms just before every nasal airway resistance measurement
Outcomes Primary outcome: changes in nasal airway resistance
Secondary outcomes: subjective symptom scores of nasal blockage, secretion, itching,
sneezing, coughing and taste sensation
Notes Funding: source of funding not indicated
Declarations of interest: not provided
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Akerlund 1989 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Methods of random sequence generation
not discussed
Allocation concealment (selection bias) Unclear risk Methods of allocation concealment not dis-
cussed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding of participants not discussed
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessment not dis-
cussed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Incomplete data were reported: “102 of the
106 patients had valid nasal airway resis-
tance measurements”
In the table the remaining number of par-
ticipants in each treatment group was pro-
vided
Selective reporting (reporting bias) Low risk All outcomes were reported
Other bias Low risk No evidence of pharmaceutical company
funding or any other sources of bias
Bye 1980
Methods Randomised, double-blind, placebo-controlled, 4-arm, parallel-group study
Participants N recruited: 466 healthy adults, 199 participants reported a total of 243 colds over a 6-
month period
N participants analysed:
• Placebo: N = 72
• Pseudoephedrine hydrochloride: N = 68
• Triprolidine hydrochloride: N = 69
• Pseudoephedrine and triprolidine: N = 54
Age: mean age 30.9 ± 10 years
Country: UK
Inclusion criteria: having a cold
Remark: homogeneity was checked for age, sex, usual number of colds each winter,
absence of allergic disorder, smoking habits, duration of symptoms and signs of fever
Exclusion criteria: taking medicines that could interfere with the study
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Bye 1980 (Continued)
Interventions Nasal decongestant dose:
Pseudoephedrine hydrochloride 60 mg
Triprolidine hydrochloride 2.5 mg
Pseudoephedrine 60 mg and triprolidine 2.5 mg
Administration: multiple doses
Oral tablets: bottles with 20 tablets; 1 tablet 3 times daily for as long as participant felt
necessary
Follow-up: 10 days
Measurements:
Subjective symptom score reported on a 4-point scale for:
- 12 symptoms relating to common cold (cold in the head, running nose, sneezing,
blocked nose, sore throat, headache, cough, feeling ill, phlegm, hoarseness, ache in the
back or limb and feeling feverish)
- 4 possible unwanted effects of treatment (palpitations, sleepiness, drowsiness and dry
mouth)
- 3 unlikely effects (not specified)
Outcomes Primary outcome: severity of 12 subjective symptoms
Secondary outcomes:
Severity of unwanted effects of treatment or served as an index of suggestibility
Overall impression while taking tablets
Notes Funding: source of funding not indicated
Declarations of interest: not provided
Note: unit of analysis is number of colds and not patients (some patients have more than
1 cold)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation lists were used: “Drugs
were allocated from separate randomisation
lists for men and women aged below and
above 40 years and at each centre (16 lists
in all). Balance in numbers was arranged
after every eight person in each list”
Allocation concealment (selection bias) Low risk Drugs were issued in coded bottles: “Drugs
were issued to patients in coded bottles.
All tablets were identical in appearance. All
were specially made and differed in appear-
ance from marketed preparations”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The appearance of the tablets was identi-
cal: “Drugs were issued to patients in coded
bottles. All tablets were identical in appear-
ance. All were specially made and differed
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Bye 1980 (Continued)
in appearance frommarketed preparations”
However, patients were also asked ’do
you think the trial tablets you took were
placebo’; about 75% of the patients on
placebo indicated that they thought they
were on placebo compared to 45% in the
treatment group
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Methods of outcome assessment blinding
not discussed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Incomplete data are described and in the
tables the number of remaining partici-
pants per treatment group are provided:
“Three stopped taking tablets (and com-
pleting the diary) because of unwanted side
effects; two because of excessive drowsi-
ness while taking triprolidine and one be-
cause urticaria developed during treatment
with pseudoephedrine. No reasons were
obtained from the other volunteerswhodid
not complete diaries”
Selective reporting (reporting bias) High risk Separate results for the 12 primary symp-
toms were not provided. Only the signifi-
cant difference for sneezing was discussed
Other bias Unclear risk Funding organisation is not described
Some patients had more than 1 cold over
the 6-month period. It is not clear if these
participants received the same treatment or
were randomised again
Cohen 1978
Methods Randomised, double-blind, placebo-controlled, 4-arm, parallel-group study
Participants N recruited: 80 male and female
N analysed: all 80 participants
As we focus on monotherapy in this review, only results for phenylpropanolamine-
only and placebo groups were extracted. Randomisation ratio was not clearly stated, we
assumed equal numbers in the different treatment groups:
• Phenylpropanolamine: N = 20
• Mixture of aromatic oils: N = 20
• Aromatic oils with phenylpropanolamine: N = 20
• Placebo: N = 20
Age: not stated
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Cohen 1978 (Continued)
Country: USA
Inclusion criteria:
Acute nasal congestion due to common cold
Symptoms for less than 48 hours
Exclusion criteria:
No anatomical nasal obstruction
No significant metabolic, cardiovascular or bronchopulmonary disease
Interventions Nasal decongestant dose:
Phenylpropanolamine, 37.5 mg
Placebo
Administration: single dose
Oral syrup: the study preparations were given as identically appearing cherry-flavoured
hydroalcoholic syrups
Follow-up: 1 day
Measurements: nasal airway resistance was measured by electronic posterior rhinometry
All resistance readings were made at a reference flow rate of 0.5 L/s and were the means
of 3 successive determinations of inspiratory and expiratory flow
Total nasal resistance was calculated as the sum of mean inspiratory and expiratory
resistances
Participants were asked to grade their nasal congestion using a 6-ranked scale ranging
from 1 (no congestion) to 6 (very severe congestion)
After treatment, measurements were recorded 15, 30, 60, 120, 180 and 240 min from
baseline
No smoking or meals before and during the trial
Outcomes Primary outcome: nasal airway resistance
Secondary outcome: subjective rating of nasal obstruction
Notes Funding: source of funding not indicated
Declarations of interest: not provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A randomisation code was used: “The four
study preparations were given as identi-
cally-appearing cherry flavoured hydroal-
coholic syrups in double-blind fashion ac-
cording to the randomisation code”
“The four formulations and the coded ran-
domised allocation were prepared under
the supervision of Mr. Robert Kirpitch,
Senior Clinical Scientist, Warner-Lambert
Research Institute, Morris Plains, N.J”
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Cohen 1978 (Continued)
Allocation concealment (selection bias) Low risk The treatment and placebo preparations
looked identical: “The four study prepa-
rations were given as identically-appearing
cherry flavoured hydroalcoholic syrups in
double-blind fashion according to the ran-
domisation code”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk It was stated that treatment was allocated
in a double-blind fashion under the su-
pervision of a senior scientist: “The four
study preparations were given as identi-
cally-appearing cherry flavoured hydroal-
coholic syrups in double-blind fashion ac-
cording to the randomisation code”
“The four formulations and the coded ran-
domised allocation were prepared under
the supervision of Mr. Robert Kirpitch,
Senior Clinical Scientist, Warner-Lambert
Research Institute, Morris Plains, N.J”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Methods of blinding outcome assessment
were not discussed
Incomplete outcome data (attrition bias)
All outcomes
Low risk In the results it was reported that all par-
ticipants were able to co-ordinate with the
method and completed their protocol as-
signments
Selective reporting (reporting bias) Low risk All scores for all outcome measures were
reported
Other bias Low risk No evidence of pharmaceutical company
funding or any other sources of bias
Eccles 2005
Methods Randomised, double-blind, placebo-controlled, parallel-group
Participants N recruited: 238
N analysed: 238
- Placebo: N = 119
- Pseudoephedrine: N = 119
Participants that were protocol valid: 236 for day 1 and 230 for day 3; not clear how
many were placebo or pseudoephedrine
We assume equal numbers in each group
Age: between 18 and 65 years, mean age 20 years
Country: UK
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Inclusion criteria:
• Patients suffering from nasal congestion due to upper respiratory tract infection
• Between 18 and 65 years
• General good health
• Acceptable methods of birth control for duration of the study
Exclusion criteria:
• Pregnant or lactating
• Clinical history deemed by the physician as a reason for exclusion: ischaemic heart
disease, angina, cardiac arrhythmias, hypertension, history of renal failure, history of
perennial allergic rhinitis (patients with a history of seasonal allergic rhinitis were not
excluded when patients were recruited out of season)
• Nasal polyps
• History of benign prostatic hypertrophy
• History of bacterial sinusitis in previous 2 weeks
• Use of antibiotics prior to study entry
• Use of tricyclic antidepressants or monoamine oxidase inhibitors
• Smokers who could not abstain from smoking during lab visits
Diagnostic criteria:
• Patients suffering from nasal congestion due to upper respiratory tract infection
• Score of 3 (moderate) for nasal congestion on a 7-point scale
• Cold symptoms began within 72 hours
• Nasal airway resistance 0.2 ≥ Pa/cm³/s at baseline on day 1
Interventions Nasal decongestant dose:
Sudafed tablets containing 60 mg of pseudoephedrine hydrochloride
Matched placebo tablets
Administration: multiple doses
Oral tablets: patients were instructed to take the tablet 4 times a day (every 4 to 6 hour)
for 3 days
Follow-up: 3 days
Measurements:
Total nasal airway resistance was measured with posterior rhinomanometry at a sample
pressure of 75 Pa at baseline and every 60 min on day 1 and day 3 up until 4 hours after
dosing
Subjective nasal congestion: measured with a 100 mm visual analogue scale: 0 = nose
completely clear, 100 = nose completely blocked. Symptoms of nasal congestion/stuffi-
ness and nasal discharge/runny nose were scored on a 7-point ordinal scale at baseline
and at 6 PM on days 1 and 2
Outcomes Primary outcome: AUC of the NAR from 0 to 3 hours after the first dose on day 1
Secondary outcomes:
• Nasal airway resistance AUC 0 to 4 hours after the first dose on day 1
• Nasal airway resistance AUC 0 to 3 hours after the last dose on day 3
• Nasal congestion measured on a symptom scale: AUC 0 to 3 and 0 to 4 hours
after the first dose day 1, and after the last dose day 3
• Mean change from baseline in nasal stuffiness and runny nose score over 3 days
Notes Funding: Pfizer Consumer HealthCare
Declarations of interest: not provided, but one author was employed by Pfizer
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A randomisation codewas used: “Themed-
ication and randomisation code were pre-
pared by Pfizer Consumer HealthCare”
Allocation concealment (selection bias) Low risk A concealed disclosure envelope was used
and placebo matched treatment: “The
identity of each treatment kitwas concealed
in a disclosure envelope only to be opened
in case of emergency”
“The allocation of medication was strati-
fied according to baseline nasal airway re-
sistance (low nasal airway resistance 0.2 to
0.4 and high nasal airway resistance ≥ 0.
41 Pa/cm³/sec)”
“Study medication consisted of 60 mg
pseudoephedrine or matched placebo
tablets”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Patients received matched placebo tablets
ensuring that participants/personnel had
no knowledge of the intervention theywere
allocated to
“Study medication consisted of 60 mg
pseudoephedrine or matched placebo
tablets”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Methods of outcome assessment blinding
not discussed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The number of missing values is described.
However, it is not clear how many persons
remained in each group:
“238 participants were recruited, 236 were
protocol-valid for day 1 and 230 were pro-
tocol-valid for day 3”
“Missingpre-dose assessmentswere not im-
puted and the corresponding AUC was set
tomissing.Missingdata forAUCwere only
imputed if either a 3- or 4-hour readingwas
missing”
Selective reporting (reporting bias) Low risk All outcomes were reported
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Other bias Unclear risk Study was funded by Pfizer
Eccles 2006
Methods Randomised, double-blind, placebo-controlled, 4-arm, parallel-group study
Participants N recruited: 384 patients were screened, 305 were randomised
N analysed: unclear from text, presumably 305:
- 76 used paracetamol and pseudoephedrine
- 76 paracetamol only
- 76 pseudoephedrine only
- 77 placebo
As we only focus on monotherapy in this review, only the results for the treatment group
on pseudoephedrine only and placebo were extracted
Age: 18 or older
Country: UK
Inclusion criteria: patients had to be in general good health and at least 18 years old
Exclusion criteria: nasal resistance within normal range at screening (≤ 0.25 Pa/cm³/s)
, history of allergic rhinitis, chronic respiratory disease, anatomical nasal obstruction or
deformity, the presence of nasal polyps, or a disease which contra-indicated the use of ei-
ther paracetamol or pseudoephedrine. Patients who had taken certainmedicationswithin
a given timescale of study entry were also excluded; astemizole (30 days), monoamine
oxidase inhibitors (14 days), antibiotics (7 days), antihistamines (72 hours), analgesics/
antipyretics (24 hours), nasal decongestants (12 hours), antitussives, medicated lozenge
or throat spray (8 hours), alcohol (6 hours) and menthol products (2 hours). Patients
using metoclopramide, domperidone, cholestyramine or anticoagulation therapy were
also excluded from the study
Diagnostic criteria: symptomatic upper respiratory tract infections of up to 3 days du-
ration, nasal congestion (i.e. total nasal airflow resistance of > 0.25 Pa/cm³/s determined
by posterior rhinomanometry) and pain of at least moderate intensity at baseline
Interventions Nasal decongestant dose:
1000 mg of paracetamol combined with 60 mg of pseudoephedrine
1000 mg of paracetamol alone
60 mg of pseudoephedrine alone
Placebo
Administration: multiple doses
Oral medication: 1 single dose given at clinic; patients were then instructed to dose as
required up to 3 times per day with minimum dosing interval of 4 hours for 3 days
Follow-up: 3 days
Measurements:
Nasal airflow conductance was calculated from measurements of nasal resistance to air-
flow (Pa/cm³/s) at a fixed sample nasal pressure of 75 Pa using posterior rhinomanometry
Pain relief of cold and flu-like symptoms (composite of sore throat, headache, body aches
and pains) was assessed using a 5-point verbal rating scale (“0 = none, 1 = a little, 2 =
some, 3 = a lot, 4 = complete relief ”)
Pain intensity (composite of sore throat, headache, body aches and pains) and nasal
congestion (4-point scale of “0 = none, 1 = mild, 2 = moderate, 3 = severe”)
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Eccles 2006 (Continued)
Global assessment of pain relief and of nasal congestion relief at the follow-up visit (5-
point scale of “0 = poor, 1 = fair, 2 = good, 3 = very good, 4 = excellent”)
Adverse events were recorded
Assessments of nasal airflow resistance and pain relief and intensity were made at 1, 2,
3 and 4 hours after dosing. Patients assessed nasal congestion and pain intensity each
evening
Outcomes Primary outcomes: nasal airflow conductance, pain relief
Secondary outcome: adverse events
Notes Funding: GlaxoSmithKline
Declarations of interest: “This study was funded by GlaxoSmithKline PLC. DR, MN,
EJ and IB are employees of GlaxoSmithKline PLC. RE has acted as a consultant to
GlaxoSmithKline PLC”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A randomisation schedule was used: “El-
igible patients were then assigned to 1 of
4 treatment regimens (the combination,
paracetamol alone pseudoephedrine alone
or placebo), in equal ratio, according to a
parallel group randomisation schedule”
Allocation concealment (selection bias) Unclear risk Methods of allocation concealment were
not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study states that it was double-blinded and
that the double-dummy method used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Study states that it was double-blinded, but
there is nomention of themethod of blind-
ing outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk The number of discontinuations per treat-
ment group is described: “No patients
withdrew due to an adverse event during
the single dose phase of the study. In the
multiple dose phase 2 patients (dry mouth
- combination treatment and vomiting -
pseudoephedrine treatment) discontinued
dosing due to adverse events”
Selective reporting (reporting bias) Low risk All intended outcomes reported
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Other bias Unclear risk Study was funded by GlaxoSmithKline
PLC
Eccles 2008
Methods Randomised, double-blind, placebo-controlled, parallel-group study
Participants N recruited: 78 were screened, 12 did not meet the inclusion criteria
66 were randomised
5 were not dosed
N analysed: 61
- Xylometazoline: N = 29
- Placebo: N = 32
Age: 18 years and over, median age 20
Country: UK
Inclusion criteria:
• Aged 18 years and over
• Male patients or non-pregnant, non-lactating female patients
• Recent onset of nasal congestion due to common cold
• Cold symptoms < 36 hours before study entry
Exclusion criteria:
• Inability to abstain from smoking for 1 hour before and for the duration of each
visit
• NAR < 0.2 Pa/cm³/s at screening visit 1
• History of perennial allergic rhinitis unless recruited out of season
• Significant abnormalities (e.g. polyps and deviated septum)
• History of transsphenoidal hypophysectomy or rhinitis medicamentosa
• Bacterial sinusitis infection during the past 2 weeks before study entry
• Use of drugs (antibiotics, alpha-adrenergics, glucocorticosteroids, antidepressants
or monoamine oxidase inhibitors)
• Use of any medication that may affect sleep as judged by the investigator
• Known hypersensitivity to xylometazoline or any excipients of Otrivin nasal spray
• Alcohol intake
• Uncontrolled arterial hypertension
Diagnostic criteria:
Minimum nasal congestion score of 2 (rated on a 4-point scale; 0 = not present; 1 =
mild; 2 = moderate; 3 = severe)
Minimum 2 common cold symptoms (runny nose, blocked nose, sore throat, cough)
Interventions Nasal decongestant dose:
Xylometazoline 0.1%, 1.0 mg/mL of F2 metered-dose nasal spray
Placebo: saline solution
Administration: multiple doses
Nasal spray: 1 spray (0.14 g) in each nostril 3 times per day until the total common cold
symptom score was recorded to be 0 or for a maximum of 10 days
Follow-up: not clear, maximum 10 days
Measurements:
Nasal airway resistance was measured using active posterior rhinomanometry at baseline,
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30 min and 1, 6, 7, 8, 9, 10, 11 and 12 hours after dosing
Subjective symptom scores: a visual analogue scale (0 = nose completely clear, 100 = nose
completely blocked); this was measured every 5 min over a 30 min period
Runny nose, blocked nose, sore throat, cough, sneezing and ear ache scores recorded
every day on a 4-point scale (0 = not present, 1 = mild, 2 = moderate, 3 = severe)
Other measures:
Subjective measures of sleep, tiredness, daily activities, general well-being, smell
Adverse events were recorded
Outcomes Primary outcomes: total nasal airway resistance
Secondary outcomes:
Time to onset of subjective relief of nasal congestion
The peak subjective relief of nasal congestion (lowest score)
Symptoms of common cold: runny nose, blocked nose, sore throat, cough, sneezing and
ear ache scores recorded on a 4-point scale
Notes Funding: Novartis
Declarations of interest: “M. Eriksson, S. Graffera, and S.C. Chen are employees of
Novartis, the clinical trial was sponsored by Novartis”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not clearly de-
scribed: “Eligible patients were randomised
in a 1:1 ratio and treated double-blind”
Allocation concealment (selection bias) Unclear risk It is not clear if participants could not fore-
see treatment allocation since they were
stratified according to severity of nasal con-
gestion:
“Patients were stratified according to sever-
ity of nasal congestion as measured by pos-
terior rhinomanometry during screening
on the first study visit (nasal airway resis-
tance, 0.2 to 0.4 and > 0.41 Pa/cm³ per
second)”
“The nasal spray devices were identical and
delivered 0.14 G/actuation”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk It is stated that treatment was administered
double-blind and “The nasal spray devices
were identical and delivered 0.14 G/actua-
tion”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Methods of blinding outcome assessment
were not discussed
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Incomplete outcome data were described
and the number of remaining participants
per treatment group is provided in the ta-
bles: “66 patients were randomised to the
study but 5 were randomised not dosed be-
cause they either did not return on day 1
of treatment (N = 4) or on returning were
unable to reproduce the technique required
for measurement of nasal airway resistance
(N = 1).” All 61 patients were included
in the intention-to-treat efficacy and safety
analysis)
Selective reporting (reporting bias) High risk Not all outcomes were reported: total nasal
airway resistance was mentioned as the pri-
mary outcome, but total nasal airway con-
ductance was reported. In the baseline table
investigators differentiated between nasal
resistance and nasal conductance; further
in the results only nasal conductance is re-
ported
Other bias Unclear risk Funded by Novartis
Eccles 2014
Methods Randomised, double-blind, placebo-controlled, 4-arm parallel-group study
Participants N recruited: 833
N analysed: 829 (4 withdrew consent)
As we only focus on monotherapy in this review, only the results for treatment group on
pseudoephedrine only and placebo were extracted
The number of patients per treatment group was not provided; from the percentage of
adverse events we calculated the following numbers:
• Aspirin and pseudoephedrine N = 236
• Aspirin N = 239
• Pseudoephedrine N = 237
• Placebo N = 121
Age: not stated
Country: UK
Inclusion criteria: nasal congestion and pain associated with upper respiratory tract
infections for no more than 3 days
Exclusion criteria:
Allergic rhinitis, chronic respiratory disease, hyperthyroidism, cardiovascular disease,
severe hypertension, peptic ulcer and hypersensitivity to acetylsalicylic acid, aspirin or
pseudoephedrine
Some medications were not allowed prior to the study entry: monoamine-oxidase in-
hibitors (30 days), antihistamines and antibiotics (7 days), analgesics and antipyretics (24
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hours), nasal decongestants (12 hours), lozenges and throat sprays (6 hours), menthol
containing products (6 hours)
Patients under anti-coagulation therapy and pregnant or lactating females were also
excluded from the study
Diagnostic criteria:
Pain score of at least moderate intensity (2 on a 4-point scale)
Total nasal airway resistance > 0.25 Pa/cm³ as determined by posterior rhinomanometry
Interventions Nasal decongestant dose:
• 1000 mg aspirin and 60 mg pseudoephedrine
• 1000 mg aspirin
• 60 mg pseudoephedrine
• Placebo
Administration: multiple doses
Sachets (small disposable bags) with granules to be dissolved in water and taken orally 3
doses per day during 3 days, with a minimum dosing interval of 4 hours
Follow-up: 3 days
Measurements:
Pain symptom score (composite score for sore throat and/or headache) recorded on a 4-
point categorical scale consisting of no pain = 0, mild pain = 1, moderate pain = 2 and
severe pain = 3
Nasal obstruction with a total nasal air flow resistance of > 0.25 Pa/cm³/s as determined
by posterior rhinomanometry; this was measured 1, 2, 3 and 4 hours after dosing
At the evening of every day patients were asked to assess pain intensity, pain relief, nasal
congestion intensity and nasal congestion relief and at day 3 they were asked for a global
assessment of pain relief and global assessment of nasal congestion relief
Adverse events were recorded during the whole study period
Outcomes Primary outcome:
Reduction of nasal congestion (nasal airflow conductance)
Secondary outcomes:
Total subjective nasal congestion relief
Global assessment of nasal congestion relief
Total pain relief
Notes Funding: Bayer HealthCare LLC
Declarations of interest: “This study was sponsored by Bayer HealthCare LLC, Mor-
ristown, NJ, USA. R.E. acted as a consultant for Bayer HealthCare LLC. M.V. is an
employee of Bayer HealthCare. The authors acknowledge the participation of the staff
at the Common Cold Centre, Cardiff University in managing and conducting the study
(Dr. M. Jawad, Miss S. Jawad, Mr. B. Pope, and Miss H. Crowdy). R.E. and staff are
employees of Cardiff University and they received no payment above normal university
salary for conducting this clinical study.”
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Methods of randomisation sequence gen-
eration not discussed
Allocation concealment (selection bias) Low risk Participants could not foresee treatment
allocation since the different treatments
had the same appearance, taste and smell:
“Double blinding was guaranteed since it
was not possible to distinguish between
combination product, monotherapies, and
placebo granules. All treatments were dis-
pensed as sachets containing white gran-
ules for dissolving in water, and they had
the same appearance, taste, and no notice-
able smell. Neither the investigators nor the
patients were aware of the nature of the
treatments and both were therefore blinded
for any assessments. The placebo contained
all the flavouring and excipients that were
present in the other medications, which
were sucrose, hypromellose binder, orange
flavour, and citric acid”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The investigators state that double-blind-
ing was guaranteed: “Double blinding was
guaranteed since it was not possible to
distinguish between combination product,
monotherapies, and placebo granules. All
treatments were dispensed as sachets con-
taining white granules for dissolving in wa-
ter, and they had the same appearance,
taste, and no noticeable smell. Neither the
investigators nor the patients were aware of
the nature of the treatments and both were
therefore blinded for any assessments. The
placebo contained all the flavouring and ex-
cipients that were present in the othermed-
ications, which were sucrose, hypromellose
binder, orange flavour, and citric acid”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Neither the investigators nor the patients
were aware of the nature of the treatments
and both were therefore blinded for any
assessments”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Themissing data are described.However, it
is not clear how many patients remained in
each treatment group: “There were 833 pa-
tients randomised 833patients randomised
to the study. All of themwere treated. 4 par-
50Nasal decongestants in monotherapy for the common cold (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Eccles 2014 (Continued)
ticipants withdrew consent, but all other
participants were included in the analyses”
Selective reporting (reporting bias) Low risk All primary and secondary outcome mea-
sures were reported
Other bias Unclear risk Study sponsored by BayerHealthCare LLC
The number of participants in each group
was not provided. Only in the methods is
a sample size calculation provided, which
yielded a total sample size of 875 (“ap-
proximately 250 patients were to be ran-
domised into each of the aspirin/ pseu-
doephedrine combination, aspirin alone,
and pseudoephedrine alone groups and
125patientswere to be randomised into the
placebo group”), whereas 833 were eventu-
ally randomised
Ferguson 1997
Methods Randomised, double-blind, placebo-controlled, parallel-group study
Participants N recruited: 97 recruited and 80 received treatment
- 67 oxymetazoline
- 13 placebo
N analysed: 82: 15 failed to return 4 to 6 weeks later
Country: UK
Age: mean age 22 years
Inclusion criteria: upper respiratory tract infection symptoms between 12 and 120
hours
Exclusion criteria: any prescribed medication other than the contraceptive pill, respi-
ratory or cardiovascular disease, secondary bacterial infection, menthol exposure in pre-
vious 12 hours, sinusitis symptoms
Diagnostic criteria: total nasal airway resistance > 0.3 Pa/cm/s
Interventions Nasal decongestant dose: 50 µg oxymetazoline hydrochloride
Placebo: spray containing only vehicle
Administration: single dose
Nasal spray: 2 sprays in each nostril
Follow-up: 1 day
Measurements: 60 min after treatment
Total nasal airway resistance measured by posterior rhinomanometry at a sample pressure
of 75 Pa. Nasal nitric oxide levels measured using a chemiluminescence gas analyser
Outcomes Primary outcome: nasal nitric oxide levels
Secondary outcome: total nasal airway resistance
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Notes Funding: Procter and Gamble Company
Declarations of interest: not provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not discussed
Allocation concealment (selection bias) Unclear risk Allocation concealment method not dis-
cussed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Methods of blindingnot clearly stated, only
that both treatment and placebo used the
same vehicle; a spray
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Methods of blinding not discussed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 15 participants failed to return, but for all
results the number of participants is indi-
cated
Selective reporting (reporting bias) Low risk All outcomes were reported
Other bias Unclear risk Commercial funding
Gronborg 1983
Methods Randomised, double-blind, placebo-controlled, cross-over design
Participants N recruited: 34
N analysed: 30 (“Four subjects were excluded as it became evident on the second day
that their cold symptoms had disappeared”)
Country: Denmark
Age: range was 18 to 32 years, mean age was 23.0 years
Inclusion criteria: a nose blowing of at least 0.1mL could be provided in the observation
period
Exclusion criteria: none stated. “Four subjects were excluded as it became evident on
the second day that their cold symptoms had disappeared”
Diagnostic criteria: sudden occurrence of sneezing, nasal discharge and blockage, or at
least of 2 of these symptoms. Nasal symptoms lasting 12 to 48 hours. The student felt
sure that he/she caught a cold. The investigator observed signs of a cold (nasal voice,
sneezing, nose blowing) during the 10 to 15 min observation period
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Interventions Nasal decongestant dose: single dose of 100 mg norephedrine in a sustained release
form
Administration: single dose
Oral tablets (cross-over design: each participant received treatment on 1 day and placebo
on another day)
Follow-up: 1 day
Measurements: nasal airway resistance measured by posterior rhinomanometry and
nasal peak flow measured immediately after rhinomanometry, using a Write Peak Flow
minimeter. This was measured before and 2 hours after treatment
Self-assessment test for nasal blockage (scale from 0 “completely free” to 5 “complete
blockage”) and recording of numbers of sneezes and nose blowing per hour. This was
measured hourly (2 to 10 hours after treatment)
Side effects: a questionnaire about new symptoms
Outcomes Study does not explicitly state which of the measured outcomes were primary or sec-
ondary
We assumed the following:
Primary outcomes: nasal airway resistance, nasal peak flow, self-assessment of nasal
blockage
Secondary outcomes: numbers of sneezes and nose blowing per hours, side effects
Notes Funding: H. Lundbeck and Co. funded the study and provided the medication
Declarations of interest: not provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not described,
only that “each student got a single dose of
100 mg norephedrine in sustained release
form and placebo in randomised order”
Allocation concealment (selection bias) Unclear risk No mention of allocation concealment de-
scribed but due to cross-over design, all pa-
tients enrolled in the study received both
treatment and placebo
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study reports that it is double-blind: “the
tablets were supplied in coded vials by
H. Lundbeck and Co., Copenhagen, Den-
mark”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study reports that it is double-blind. For
rhinomanometry, because “the reading of
the V2 value depends to some degree
upon the investigator’s interpretation of the
curve”, “in order to eliminate this as a po-
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tential source of bias, [the authors] have
added a computer to the set-up, which dig-
itally displays the means V2 value of five
consecutive respiration curves.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4 of the original 34 students who fulfilled
the inclusion criteria “were excluded as it
became evident on the secondday that their
cold symptoms had disappeared”. The re-
maining 30 students completed the trial
Selective reporting (reporting bias) Low risk All intended outcomes were reported
Other bias Unclear risk H. Lundbeck andCo. funded the study and
provided the medication
Jawad 1998
Methods Open, randomised, parallel-group, placebo-controlled study
Participants N recruited: 40
N analysed: 40
20 pseudoephedrine
20 placebo
Age: range 18 to 49 years, mean 23 years
Country: UK
Inclusion criteria: patients with nasal congestion associated with a history of common
cold for less than 96 hours
Exclusion criteria: anatomical nasal obstruction or gross anatomical deformity, includ-
ing moderate or severely deviated septum or the presence of nasal polyps; taken menthol
lozenges or a menthol containing product in the past hour; taken any nasal decongestant
in the past 12 hours; taken any antihistamine in the last 72 hours or astemizole in the
last 30 days; taken any analgesic in the last 24 hours; taken any prescribed medication
within the last 30 days (with the exception of the contraceptive pill); a history of hyper-
thyroidism, diabetes mellitus, heart disease prostatic hypertrophy or hypertension
Diagnostic criteria: subjective score of 2 (moderate) for blocked nose, and at least 1
(mild) for any other cold symptoms. Patients were screened by the physician and a
medical history was taken; blood pressure and pulse were measured
Interventions Nasal decongestant dose:
Pseudoephedrine 60 mg tablet
Placebo (Sanatogen multi-vitamin tablet)
Administration: multiple doses
Oral tablets (2 doses on the same day with a 4-hour interval)
Follow-up: 1 day
Measurements:
Unilateral nasal airflow was measured using posterior rhinomanometry at an inspiratory
reference pressure of 75 Pa with an oral cannula to sense posterior nasal pressure. Mea-
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sured 1 hour after the first dose of medication and then every hour over a 7-hour period
In this study nasal patency has been expressed in terms of nasal airflow at a reference
pressure of 75 Pa, rather than as nasal resistance because nasal resistance tends towards
infinity with nasal obstruction whereas nasal airflow tends towards zero. We assume this
is nasal airway conductance
Patients were asked to score their common cold symptoms of cough, runny nose, blocked
nose and sore throat on a 5-point box scale with symptoms labelled 0 = not present, 1 =
mild, 2 = moderate, 3 = severe, 4 = very severe
Outcomes No distinction between primary and secondary outcomes was made
Outcomes:
Minimum and maximum unilateral airflow during the 7-hour period of study
Total nasal airflow
Notes Funding: not reported
Declarations of interest: not provided
Note: the study was not blinded
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not clearly de-
scribed:
“Treatments […] were allocated according
to a randomisation list. Those patients with
a total nasal airflow of 175 cm³/sec or less
were randomised to a low treatment group
and those with a total nasal airflow of 176
cm³/sec or greater were randomised to a
high treatment group”
Allocation concealment (selection bias) Unclear risk No method of allocation concealment
mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The study was not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The study was not blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of patients involved in study is
stated once in the results, with no mention
of discontinuations or exclusions through-
out the study
Selective reporting (reporting bias) Low risk All intended outcomes reported
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Other bias Low risk No pharmaceutical funding or other
sources of bias identified
Latte 2004
Methods Randomised, double-blind, placebo-controlled, parallel-group study
Participants N recruited: 50
N analysed: 48
- 24 pseudoephedrine
- 24 placebo
Age: range 18 to 52 years, mean age of 23 years
Country: Australia
Inclusion criteria: 18 years of age or older, healthy
Exclusion criteria: nasal deformity, chronic obstruction, participants on vasoactive or
nasally active drugs, or a drug with a potential interaction with pseudoephedrine, history
of severe (greater than 2 weeks duration each year) allergic rhinitis
Diagnostic criteria: symptoms of coryza for less than 48 hours, including at least ‘mod-
erate’ symptoms of nasal congestion and a ‘mild’ sore throat or runny nose (on self-
assessed scales of none/mild/moderate/moderate severe/severe) at the time of the study
Interventions Treatment before study: none
Nasal decongestant dose:
Pseudoephedrine tablet 60 mg
Placebo
Administration: single dose
Oral tablet
Follow-up: 1 day
Measurements:
Acoustic rhinometry and active posterior rhinomanometry at 75 Pa
Subjective ratings of nasal congestion, measured on a 100 mm visual analogue scale an-
chored by the descriptors “nose completely clear” (0mm) and “nose completely blocked”
(100 mm)
Baseline measurements were conducted at 20 min intervals for 1 hour, followed by
dosing with the study treatment. Post-treatment, 2 hours of serial measurements were
undertaken at 20 min intervals
Outcomes Primary outcomes: total volume and total minimum cross-sectional area inside nasal
cavity
Secondary outcomes: nasal airway resistance, visual analogue scale for perception of
congestion
Notes Funding: source of funding was not provided, but the treatment medication was 60 mg
SudafedTM tablet; Pfizer Consumer HealthCare Group (Caringbah, NSW, Australia)
Declarations of interest: not provided
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Treatment randomisation was from a ran-
dom numbers table, in blocks of four”
Allocation concealment (selection bias) Low risk “To conceal treatment allocation, the pseu-
doephedrine and placebo were placed in
identical opaque gelatine capsules”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The pseudoephedrine and placebo were
placed in identical opaque gelatine cap-
sules”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of method of blinding out-
come assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients were accounted for
Selective reporting (reporting bias) Low risk All intended outcomes were reported
Other bias Low risk No (clear) pharmaceutical funding or other
sources of bias identified
Latte 2007
Methods Randomised, double-blind, placebo-controlled, parallel-group study
Participants N recruited: 216
N analysed:
- Placebo: N = 105
- Pseudoephedrine: N = 107
212 had complete data on visit 1
210 had complete data on visit 2
211 completed treatment on day 3
It is not indicated how many participants of the treatment group or placebo group had
complete data on day 2 and 3
Age: 18 to 65 years
Country: Australia
Inclusion criteria:
• Nasal congestion due to the common cold
• Male and female
• Aged 18 to 65 years
• Good general health
• Suffering from common cold <= 48 hours
Exclusion criteria:
• Women who were pregnant or lactating, or not using an appropriate form of
57Nasal decongestants in monotherapy for the common cold (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Latte 2007 (Continued)
contraception
• History of perennial allergic rhinitis
• Unstable medication
Diagnostic criteria: episode of common cold no more than 48 hours duration before
visit 1
Interventions Nasal decongestant dose:
Pseudoephedrine 60 mg
Placebo
Administration: multiple doses
Oral tablets; 1 tablet 4 times a day for 4 days
Follow-up: 4 days
Measurements:
Total nasal airways resistance was measured using the posterior rhinomanometry tech-
nique
Total nasal volume and total minimum cross-sectional area weremeasured using acoustic
rhinometry
A 100 mm visual analogue scale from 0 mm to 100 mm was used to assess symptoms of
nasal congestion
Subjective measurements on a 7-point categorical scale for the previous 24 hours (0 none
to 6 incapacitating)
- worst levels of congestion
- worst levels of nasal discharge
- worst levels of sneezing
Measurements were performed hourly (for 4 hours) after the first dose on day 1 and after
the last dose on day 4
Outcomes Primary outcome: the area under the logarithm-transformed total nasal airways resis-
tance curve from 0.5 to 3 hours after the first dose of study medication on day 1
Secondary outcomes:
The area under the curve for the total minimum cross-sectional area of the combined
left and right nasal cavities from 0 to 3 hours on day 1 and 3
The area under the curve for the total nasal volume of the combined left and right nasal
cavities from 0 to 3 hours on day 1 and 3
The area under the curve for the nasal congestion visual analogue scale from 0 to 3 hours
on day 1 and 3
Notes Funding: Pfizer Consumer Health Care
Declarations of interest: not provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A randomisation schedule was used: “Med-
ication was allocated blindly according to a
centrally generated randomisation code”
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Allocation concealment (selection bias) Unclear risk Study reports that “medication was allo-
cated blindly”, but method of allocation
concealment not clearly stated. Only that
“subjects were given treatments consisting
of either active medication […] or match-
ing placebo”. However, it is not clear if par-
ticipants could not foresee assignment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study reports that it was double-blind, but
methods of blinding not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Study reports that it was double-blind, but
there is no mention of method of blinding
outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk There are 6 dropouts throughout the study,
but only 1 discontinuation is explained in
the text. The number of remaining partic-
ipants in each treatment group is not clear
Selective reporting (reporting bias) Low risk All intended outcomes reported
Other bias Unclear risk Study supported by Pfizer Consumer
Health Care
Reinecke 2005
Methods Randomised, double-blind, placebo-controlled, multi-centre, parallel-group study
Participants N recruited: 247
N analysed: 247
Number of participants per treatment group not reported but we assume equal numbers
(1 extra in the treatment group)
- Oxymetazoline N = 124
- Placebo N = 123
Age: older than 12
Country: Germany
Inclusion criteria:
Patients with acute rhinitis, clinically healthy
Duration of symptoms: not more than 48 hours
Exclusion criteria:
Patients could not use other nasal decongestants that work by stimulating the alpha-
adrenergic receptors, antihistamines, corticosteroids and other medication against the
common cold including analgesics
Diagnostic criteria: none documented
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Interventions Treatment before study: not clear if the medication that was listed as an exclusion was
not allowed during the first 48 hours before inclusion
Nasal decongestant dose:
- Oxymetazoline: dose not described
- Saline nose spray
Administration: multiple doses
Nasal spray: patients were allowed to administer the treatment/placebo 3 times a day
until the symptoms disappeared (maximum of 10 days)
Follow-up: 10 days
Measurements: patient reports
Outcomes Primary outcome: number of days until full recovery
Secondary outcomes: seconds until some improvementwas perceived after a single dose,
global satisfaction with treatment, reported symptoms, safety (i.e. satisfaction as rated
by patients and doctors, blood pressure, heart rate and adverse events)
Notes Funding: source of funding not reported
Declarations of interest: not provided
Note: only a summary of the study was available; the authors refer to a full version of
the study results, however we were not able to find this extensive version
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Methods of random sequence generation
not reported
Allocation concealment (selection bias) Unclear risk Patients were randomised in each centre
but methods of allocation concealment
were not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding of participants not discussed
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome not discussed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 247 patients were included, but data for
only 214 are reported for the primary out-
come. The reason for excluding 33 partic-
ipants from analysis is not reported
Selective reporting (reporting bias) High risk Not all outcomes that were described in the
methods were reported in the results (only
a summary of the study was available; the
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authors refer to a full version of the study
results, however we were not able to find
this extensive version)
Other bias Unclear risk Not enough detail in the paper to exclude
the possibility of other bias (e.g. funding
and recruitment strategies not described)
Sperber 1989
Methods Randomised, double-blind, placebo-controlled, 3-arm, parallel-group study
Participants N recruited: 58
N analysed: 56
All participants were included in the evaluation of tolerance, whereas analysis of efficacy
was based only on infected participants
As we only focus on monotherapy in this review, only the results for treatment group on
pseudoephedrine only and placebo were extracted
- Pseudoephedrine: N = 23
- Pseudoephedrine and ibuprofen: N = 23
- Placebo: N = 10
Age: mean age 21
Country: USA
Inclusion criteria: serumneutralising antibody titter of≤ 1:2 to the challenge rhinovirus
Exclusion criteria:
Upper respiratory symptoms or fever within 1 week prior to initiation of the study
History of active or chronic sinusitis, asthma or recent hay fever
Required use of antihistamines, systemic or topical nasal decongestants, aspirin or other
nonsteroidal anti-inflammatory drugs, monoamine oxidase inhibitors or phenothiazines
Had a history of hypersensitivity to aspirin or other anti-inflammatory drugs, pseu-
doephedrine or other sympathomimetics
Were pregnant or lactating
Would be smoking during the study period
Diagnostic criteria: none as patients were inoculated with virus at the beginning of the
study
Interventions Treatment before study: experimentally induced rhinovirus colds: intranasal rhinovirus
challenge was administered in 2 inocula over a 15-min period by a calibrated pipette (50
µL per nostril) with the participant supine
Nasal decongestant dose:
Pseudoephedrine 60 mg
Pseudoephedrine 60 mg and ibuprofen 200 mg
Placebo
Administration: multiple doses
Oral capsules. 2 doses were given the first day. On the subsequent 4 days, the drug was
administered 4 times daily for a total of 18 doses
Follow-up: 4 days
Measurements:
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Infection: nasal washings were collected prior to virus inoculation and each morning on
days 2 through 6 after challenge. Infection was defined as seroconversion and/or recovery
of the challenge virus from nasal washings on at least 1 day
Illness: twice daily recording of the volunteers’ symptoms: nasal (discharge, obstruction,
sneezing), throat (sore throat, hoarseness, cough) and systemic (headache, chills, fever-
ishness, malaise) on a 4-point scale (0 to 3, absent to severe). The higher of the 2 daily
ratings was used as the score for that day
The need for concomitant medications dispensed for cold symptoms
Participants were questioned twice daily concerning the presence of any unusual symp-
toms potentially referable to drug toxicity
Objective measures of illness severity included morning and evening oral temperatures;
daily collection of nasal tissues for tissue counts and determination of nasal secretion
weights
Blood pressure was measured 3 times and pulse rate once daily in all participants during
the study period
Outcomes There is no distinction between primary and secondary outcomes in the text
Outcomes: infection and virus shedding rates post-infection, symptom scores, mucus
weight, nasal tissue count, rates and indication for use of acetaminophen in infected
patients, nasal patency, adverse events
Notes Funding: funded by Richardson-Vick’s Research Center Shleton, CT, and by a grant of
the National Institute of Allergy and Infectious Diseases
Declarations of interest: not provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No method of sequence generation re-
ported
Allocation concealment (selection bias) Unclear risk No method of allocation concealment re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study reports that it is double-blinded, but
no method reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Study reports that it is double-blinded, but
no method reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients are accounted for
Selective reporting (reporting bias) Low risk All intended outcomes reported
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Other bias Unclear risk Funded by Richardson-Vick’s Research
Center and also supported by The Aspirin
Foundation of America
Taverner 1999
Methods Randomised, double-blind, placebo-controlled, parallel-group study
Participants N recruited: 99 participants were screened
54 satisfied the inclusion and exclusion criteria
N analysed: 52 completed the study
- 25 pseudoephedrine
- 27 placebo
Age: range 18 to 55 years, mean age 26 (± 9 years)
Country: Australia
Inclusion criteria:
Symptoms of an acute common cold (defined as acute nasal congestion, combined with
rhinorrhoea and/or a sore throat) for less than 5 days, acute viral upper respiratory
tract infections (defined by presence of pharyngeal erythema and moderate-severe nasal
obstruction as examined by anterior rhinoscopy)
Exclusion criteria:
Hay fever, broncho-pulmonary disease, anatomical nasal obstruction, hypertension, prior
ingestion of vasoactive drugs, caffeine and alcohol
Diagnostic criteria:
Symptoms of an acute common cold (defined as acute nasal congestion, combined with
rhinorrhoea and/or a sore throat) for less than 5 days, acute viral upper respiratory
tract infections (defined by presence of pharyngeal erythema and moderate-severe nasal
obstruction as examined by anterior rhinoscopy)
Interventions Nasal decongestant dose: 60 mg pseudoephedrine
Administration: single dose
Oral tablets, dose administered within 10 min of baseline
Follow-up: 1 day
Measurements:
Acoustic rhinometry: total minimal cross-sectional area and total nasal volume
Active posterior rhinomanometry: total nasal airway resistance
Subjective congestion: a 5-point categorical score: 0 = no congestion; 4 = severe conges-
tion
Measurements were performed at 30-min intervals until 180 min after dosing
Outcomes Primary outcome: changes in nasal congestion measured by total minimal cross-sec-
tional area, total nasal volume and total nasal airway resistance
Secondary outcomes: subjective symptoms of nasal congestion and adverse effects
Notes Funding: Procter & Gamble Technical Centres Ltd.
Declarations of interest: not provided
Risk of bias
63Nasal decongestants in monotherapy for the common cold (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Taverner 1999 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A randomisation scheme was used: “El-
igible subjects were allocated in a dou-
ble-blind randomisation schedule which
assigned subjects to 1 of the 2 rhi-
noanemometers/acoustic rhinometers used
in this study and to the pseudoephedrine
or placebo group in equal numbers”
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not dis-
cussed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The randomisation code was not broken
until all data, including delayed adverse
events had been allocated”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Incomplete data are discussed and the
number of remaining participants for each
treatment group is provided: “Of the 54
subjects who were entered randomisation,
2 failed to complete the study”
Selective reporting (reporting bias) Low risk All pre-specified outcomes were reported
Other bias Unclear risk Commercial funding: Procter & Gamble
Technical Centres Ltd
AUC: area under the curve
NAR: nasal airway resistance
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ackerhans 1994 Participants had acute rhinitis
Anderson 1956 Not a RCT
Anonymous 1975 Not a RCT
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Ashe 1968 Participants had nasal obstruction due to various reasons including allergy
Bailey 1969 Participants had nasal obstruction due to various reasons including allergy
Bende 1984 Participants had nasal obstruction, not due to common cold
Bende 1985 Nasal stuffiness was the only inclusion criterion, hence it is not clear for how long participants experienced
nasal congestion and whether this was due to the common cold
Broms 1982 Participants suffered from nasal obstruction for more than 6 months
Castellano 2002 Participants had reduced airflow, which was not necessarily due to the common cold
Cohen 1977 Combination therapy
Connell 1969 Some of the patients had allergic rhinitis
De Paula Neves 1966 Combination therapy
Dorn 2003 Trial was not placebo-controlled
Fox 1967 Trial was not placebo-controlled
Hummel 1998 None of pre-specified outcome measures were reported
Katrana 1956 Not a RCT
McElhenney 1966 Not a RCT
Meurman 1975 Trial was not placebo-controlled
Pritchard 2014 Participants with hay fever were also included
Rumiantsev 1993 Combination therapy
Smith 1999 Not an RCT
Tzachev 2002 Participants had allergic rhinitis
Weisberg 1966 Combination therapy
Winther 1983 Nasal airway resistance was not measured; the weight of nasal discharge was measured
Zumpft 1975 Participants had allergic rhinitis
RCT: Randomised controlled trial
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NCT00452270
Methods Double-blind, randomised, placebo-controlled trial
Participants Inclusion criteria:
1. 18 years and older
2. Have had moderate common cold symptoms for less than 36 hours
Exclusion criteria:
1. Congested/runny nose for more than 2 continuous weeks in the previous 12 months
2. Deviated septum or nasal polyps
3. Recent use of antibiotics
4. Recent sinusitis
Interventions The decongestant effect of xylometazoline in participants with common cold compared to placebo
Outcomes Primary outcome:
Rhinomanometry over a period of 12 hours
Secondary outcome:
The peak subjective effect, time to onset of subjective relief of nasal obstruction and duration of relief of nasal
obstruction
Notes Commercial funding: study sponsored by Novartis
This study was completed in April 2007, however we could not find published results for this study
NCT01062360
Methods Double-blind, randomised, placebo-controlled trial
Participants Inclusion criteria:
1. Male and female participants between 18 and 65 years of age
2. Onset of cold symptoms within 96 hours (4 days) before study participation
3. Current complaint of at least moderate sore throat at baseline
4. Current complaint of at least moderate nasal congestion at baseline
5. History of other symptoms associated with URTI during the last 4 days before study participation
6. Other findings of URTI, confirmed on the physical examination
7. Agreement to comply with the study requirements
8. Written informed consent prior to enrolment in the study
Exclusion criteria:
1. Pregnant or lactating females
2. Uncontrolled chronic diseases
3. History of hypersensitivity (allergic reaction) to ASA, any other non-steroidal anti-inflammatory drugs
(NSAIDs) or PSE
4. Any disease which significantly compromises breathing or interferes with the participant’s assessment of sore
throat. History of or active peptic ulcer.
5. Severe impaired hepatic function
6. Severe impaired renal function
7. Simultaneous intake of monoamine oxidase inhibitors
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8. Use of menthol containing tissues within 2 hours before first intake of study drug. Intake of any menthol
containing product within 4 hours before first intake of study drug.
9. Use of any local or systemic short-acting cough and cold preparations within 6 hours before first intake of
study drug
10. Use of any local or systemic long-acting cough and cold preparations within 12 hours before first intake of
study drug
11. Intake of any analgesic within 12 hours before first intake of study drug
12. Intake or requirement for any prescription medication for the treatment of the current acute respiratory tract
infection
13. Current or previous intake of anticoagulants, corticoids, NSAIDs, methotrexate or lithium
14. Participation in another clinical trial within the last 30 days
Interventions Compare efficacy and tolerability of a fixed combination, containing 500 mg acetylsalicylic acid and 30 mg pseu-
doephedrine, in comparison to its single components and placebo
Outcomes Primary outcome:
AUC calculated for baseline adjusted nasal congestion score for the initial 2 hours post-dosing
Secondary outcome:
Nasal congestion score: 15, 30, 60, 90, 120, 240 and 360 min
Nasal congestion relief score: 15, 30, 60, 90, 120, 240 and 360 min
Symptoms of common cold at 120 min post-dose
Notes Commercial funding: study sponsored by Bayer
The protocol was first received February 2010 and the study has been completed, however we could not find published
results for this study
ASA: acetyl salicylic acid
AUC: area under the curve
PSE: pseudoephedrine
URTI: upper respiratory tract infection
Characteristics of ongoing studies [ordered by study ID]
EUCTR2006-006690-25-GB
Trial name or title A study to evaluate the decongestant effect of Otrivin F2
Methods A double-blind, randomised, parallel-group, placebo-controlled study
Participants Inclusion criteria:
1. 18 years of age or older
2. Provide written informed consent prior to any procedures being conducted
3. Report a minimum score of 2 (moderate) for nasal congestion associated with a natural cold, according
to a 4-point scale (0 = not present, 1 = mild, 2 = moderate, 3 = severe). Report cold symptoms of a duration
less than 36 hours prior to entry to the study
4. Report a minimum of 2 common cold symptoms as present on entry to the study (runny nose,
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blocked nose, sore throat, cough)
5. Be a male or non-pregnant, non-lactating female. Women of childbearing potential defined as all
women physiologically capable of becoming pregnant, including women whose career, lifestyle or sexual
orientation precludes intercourse with a male partner and women whose partners have been sterilised by
vasectomy or other means, UNLESS they meet the following definition of post-menopausal: 12 months of
natural (spontaneous) amenorrhoea or 6 months of spontaneous amenorrhoea with serum FSH levels > 40
mL U/m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy OR are using 1 or
more of the following acceptable methods of contraception: surgical sterilisation (e.g. bilateral tubal
ligation, vasectomy), hormonal contraception (implant-table, patch, oral) and double barrier methods (any
double combination of L IUD, male or female condom with spermicidal gel, diaphragm, sponge, cervical
cap). Acceptable methods of contraception may include total abstinence at the discretion of the Investigator
in case where the age, career, lifestyle or sexual orientation of the subject ensures compliance. Periodic
abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not
acceptable methods of contraception. Reliable contraception should be maintained throughout the study
6. Be willing and able to comply with the requirements of the study; most particularly willing to undergo
measurement of total nasal airway resistance using active posterior rhinomanometry and able to record sign/
symptom scores
Exclusion criteria
1. Inability to abstain from smoking for 1 hour before and the duration of each visit
2. NAR of < 0.2 Pa/cm³/s at screening visit 1
3. A history of perennial allergic rhinitis (defined as congested/runny nose for more than 2 continuous
weeks in the previous 12 months). (Subjects with a history of seasonal allergic rhinitis will not be excluded
from participation in the study if recruited out of season
4. A clinically significant abnormality as determined by the investigator
5. Participation in a trial of an investigational drug or device within 30 days
6. Obstructive nasal polyps or significant nasal tract structural malformations including a deviated
septum or a concha bullosa as documented by physical exam
7. A history of trans-sphenoidal hypophysectomy
8. A history of rhinitis medicamentosa
9. A bacterial sinusitis infection during the past 2 weeks prior to study entry
10. Use of antibiotics or alpha adrenergic drugs (all forms) within the past 1 week, use of
glucocorticosteroids (all forms) within the past month
11. Use of any medication that may affect sleep as judged by the investigator
12. A known hypersensitivity to or idiosyncratic reaction to xylometazoline or any of the excipients
13. Regular intake of more than 6 units (as defined in UK medical practice) of alcohol daily
14. Use of antidepressant drugs or monoamine oxidase inhibitors
15. Employment of the subject or their immediate family members at the clinical research centre
16. A diagnosis of arterial hypertension which is not well controlled
17. Previous participation in this trial
18. Considered unsuitable for entry into the study by the Clinical Investigator
Interventions The decongestant effect of xylometazoline hydrochloride (Otrivin® F2) in participants with common cold
compared to placebo treatment
Outcomes Primary outcome:
The upper airway conductance at 1 hour
Starting date Not known
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Contact information Not known
Notes Commercial funding: sponsored by Novartis Consumer Health SA
This study record was entered in EuraCT in 2007, however it is indicated as still ongoing
NCT01744106
Trial name or title A multicentre study of pseudoephedrine for the temporary relief of nasal congestion in children with the
common cold
Methods Multicentre, randomised, double-blind, placebo-controlled study
Participants Inclusion criteria:
1. Male or female participants, ages 6 through 11 years, are experiencing the common cold, but are
otherwise healthy
2. Subjects have an onset of cold symptoms within the past 2.5 days before screening and are
experiencing self-reported nasal congestion of at least stuffy severity (score = 3 or 4)
3. Subjects have at least 2 of the following additional symptoms due to common cold: runny nose,
sneezing, sore throat, headache, body ache and cough, as deemed by the parent
4. Subjects can swallow oral tablets without chewing them (based on a pretest of successfully swallowing a
placebo tablet at screening)
5. Findings from the medical history review and vital signs are within the range of clinical acceptability, as
determined by the investigator
6. Subject and legally authorised representative are likely to be compliant and complete the study
7. Subject’s legally authorised representative has signed and dated the informed consent form. Subject has
given verbal assent, and has signed and dated the informed assent form
8. Female participants who have reached menarche must have a negative urine pregnancy test at
screening. These participants must have practised abstinence for at least 3 months prior to study entry and
for the duration of the study. A second pregnancy test will be given when the subject returns to the clinic
after the last dose
9. Subject and legally authorised representative can read and understand English
10. Subject’s legally authorised representative who signs informed consent is available to administer all
assessments and study medication on days 1 and 2
Exclusion criteria:
1. Have any of the following medical conditions: heart disease, high blood pressure, thyroid disease,
diabetes, peripheral vascular disease, increased intraocular pressure, prostatic hypertrophy
2. Are under treatment for a hyperexcitability disorder with a medication regimen that has not been
stable for at least 3 months
3. Are currently experiencing an asthmatic episode
4. Are experiencing symptoms of seasonal or perennial allergic rhinitis
5. Are currently or within the last 24 hours having symptoms of vomiting or diarrhoea
6. Have been exposed to immediate family members with the flu within the past week
7. Are exhibiting signs or symptoms of, or diagnosed with sinusitis, pneumonia, strep throat, acute otitis
media or influenza
8. Are experiencing a fever 103
F or higher at screening
9. Are from homes where there is smoking in the home around the child
10. Are currently taking a monoamine oxidase inhibitor (MAOI), or have taken a MAOI within 2 weeks
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of screening (e.g., isocarboxazid - Marplan, phenelzine - Nardil, selegiline - Eldepryl, Emsam, Zelapar, and
tranylcypromine - Parnate). Note: participants may not discontinue taking a MAOI solely of the purposes
of qualifying for the study
11. Have a known sensitivity or allergy to pseudoephedrine, phenylephrine or acetaminophen or any of
the excipients of the drug product
12. Have taken any oral cold or allergy medicine within 12 hours of enrolment, or intranasal
decongestants within 24 hours of enrolment except for single-ingredient over-the-counter analgesics
13. Have the need to take additional medications, including cough and cold (i.e. oral or intranasal
antihistamines, intranasal steroids, intranasal decongestants), or herbal/dietary supplements during the
study, with the exception of acetaminophen, a medication regimen for a hyperexcitability disorder that has
been stable for at least 3 months or a daily vitamin or multi-vitamin/multi-mineral supplement
14. Have participated in another clinical study within 30 days before entry
15. Have another child from the household currently participating in this study
16. Have a history of drug, alcohol or tobacco use (older children)
17. Are involved directly or indirectly with the conduct and administration of this study (i.e. children of
principal investigator, sub-investigator, study co-ordinators, other study personnel, employees of Perrigo and
the families of each)
Interventions The temporary relief of nasal congestion due pseudoephedrine versus placebo
Outcomes Primary outcome:
Nasal congestion severity (instantaneous) scores - Day 1
Weighted sum of change from baseline in nasal congestion severity (instantaneous) scores over the first 8
hours of treatment on Day 1
Secondary outcomes:
Change from baseline in nasal congestion severity (instantaneous) scores from 0 to 4 hours - Day 1
Sum of change from baseline in nasal congestion severity (instantaneous) scores from 0 to 4 hours after the
first dose on Day 1
Change from baseline in nasal congestion severity (instantaneous) scores from 6, 7, and 8 hours - Day 1
Weighted sum of change from baseline in nasal congestion severity scores (instantaneous) from 6, 7 and 8
hours after the first dose on Day 1
Nasal congestion relief reflective scores at 4 hours and 8 hours - Day 1
Sum of nasal congestion relief (reflective) scores at 4 hours and 8 hours on Day 1
Nasal congestion severity scores (instantaneous) score at each time point from 0 to 8 hours - Day 1
Nasal congestion severity scores (instantaneous) score at each time point from 0 to 8 hours after the first dose
on Day 1
Nasal congestion relief (reflective) scores at 6 hours and 12 hours - Day 2
Sum of nasal congestion relief (reflective) scores at 6 hours and 12 hours on Day 2
Nasal congestion relief (reflective) scores at 6 and 12 hours - Day 2
Nasal congestion relief (reflective) scores at 6 and 12 hours on Day 2
Starting date November 2012
Contact information Only contact information of participating centres is available: e.g
United States, California
Emmaus Research Center
Anaheim, California, United States, 92804 Contact: Filipinas Vitug 714-826-8800
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NCT01744106 (Continued)
Notes Commercial funding: sponsored by Perrigo Company in collaboration with McNeil Consumer Healthcare
Division of McNEIL-PPC, Inc. Pfizer, and Novartis Pharmaceuticals
Estimated completion date: was initially April 2015 and recently updated to May 2016
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D A T A A N D A N A L Y S E S
Comparison 1. Multi-dose decongestant versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Primary outcome: subjective
symptom score (mean)
2 94 Std. Mean Difference (IV, Random, 95% CI) 0.49 [0.07, 0.92]
1.1 Oral 1 33 Std. Mean Difference (IV, Random, 95% CI) 0.28 [-0.47, 1.02]
1.2 Topical 1 61 Std. Mean Difference (IV, Random, 95% CI) 0.59 [0.08, 1.11]
2 Secondary outcome: all adverse
events
7 1195 Odds Ratio (IV, Random, 95% CI) 0.98 [0.68, 1.40]
2.1 Oral 6 1134 Odds Ratio (IV, Random, 95% CI) 0.95 [0.65, 1.39]
2.2 Topical 1 61 Odds Ratio (IV, Random, 95% CI) 1.23 [0.39, 3.88]
3 Secondary outcome: adverse
events - insomnia/difficulty
sleeping
4 Odds Ratio (IV, Random, 95% CI) Subtotals only
3.1 Oral 4 623 Odds Ratio (IV, Random, 95% CI) 0.39 [0.09, 1.62]
4 Secondary outcome: adverse
events - headache
3 511 Odds Ratio (IV, Random, 95% CI) 0.89 [0.23, 3.37]
4.1 Oral 2 450 Odds Ratio (IV, Random, 95% CI) 0.58 [0.19, 1.84]
4.2 Topical 1 61 Odds Ratio (IV, Random, 95% CI) 4.0 [0.42, 38.07]
Comparison 2. All doses of decongestants versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Primary outcome: subjective
symptom score (mean)
3 146 Std. Mean Difference (IV, Random, 95% CI) 0.44 [0.11, 0.78]
1.1 Oral 2 85 Std. Mean Difference (IV, Random, 95% CI) 0.33 [-0.11, 0.77]
1.2 Topical 1 61 Std. Mean Difference (IV, Random, 95% CI) 0.59 [0.08, 1.11]
2 Primary outcome: subjective
symptom score (AUC)
2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Oral 2 260 Std. Mean Difference (IV, Random, 95% CI) 0.11 [-0.14, 0.35]
3 Secondary outcome: objective
NAR (mean)
2 332 Std. Mean Difference (IV, Random, 95% CI) 0.39 [-0.22, 0.99]
3.1 Oral 1 230 Std. Mean Difference (IV, Random, 95% CI) 0.11 [-0.14, 0.37]
3.2 Topical 1 102 Std. Mean Difference (IV, Random, 95% CI) 0.74 [0.23, 1.25]
4 Secondary outcome: objective
NAR (AUC)
2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Oral 2 260 Std. Mean Difference (IV, Random, 95% CI) 0.44 [-0.32, 1.20]
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Analysis 1.1. Comparison 1 Multi-dose decongestant versus placebo, Outcome 1 Primary outcome:
subjective symptom score (mean).
Review: Nasal decongestants in monotherapy for the common cold
Comparison: 1 Multi-dose decongestant versus placebo
Outcome: 1 Primary outcome: subjective symptom score (mean)
Study or subgroup Nasal decongestant Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Oral
Sperber 1989 23 -6 (4) 10 -7 (2) 32.2 % 0.28 [ -0.47, 1.02 ]
Subtotal (95% CI) 23 10 32.2 % 0.28 [ -0.47, 1.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
2 Topical
Eccles 2008 29 -25.71 (16.73) 32 -35.79 (16.73) 67.8 % 0.59 [ 0.08, 1.11 ]
Subtotal (95% CI) 29 32 67.8 % 0.59 [ 0.08, 1.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.023)
Total (95% CI) 52 42 100.0 % 0.49 [ 0.07, 0.92 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.48, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 2.28 (P = 0.023)
Test for subgroup differences: Chi2 = 0.48, df = 1 (P = 0.49), I2 =0.0%
-2 -1 0 1 2
Favours placebo Favours nasal decongestant
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Analysis 1.2. Comparison 1 Multi-dose decongestant versus placebo, Outcome 2 Secondary outcome: all
adverse events.
Review: Nasal decongestants in monotherapy for the common cold
Comparison: 1 Multi-dose decongestant versus placebo
Outcome: 2 Secondary outcome: all adverse events
Study or subgroup Nasal decongestant Placebo Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Oral
Bye 1980 19/72 15/68 21.4 % 1.27 [ 0.58, 2.75 ]
Eccles 2005 5/119 5/119 8.0 % 1.00 [ 0.28, 3.55 ]
Eccles 2006 5/77 4/76 7.0 % 1.25 [ 0.32, 4.84 ]
Eccles 2014 14/121 28/237 27.7 % 0.98 [ 0.49, 1.93 ]
Latte 2007 13/105 20/107 22.5 % 0.61 [ 0.29, 1.31 ]
Sperber 1989 2/10 4/23 3.6 % 1.19 [ 0.18, 7.84 ]
Subtotal (95% CI) 504 630 90.2 % 0.95 [ 0.65, 1.39 ]
Total events: 58 (Nasal decongestant), 76 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.02, df = 5 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.80)
2 Topical
Eccles 2008 9/32 7/29 9.8 % 1.23 [ 0.39, 3.88 ]
Subtotal (95% CI) 32 29 9.8 % 1.23 [ 0.39, 3.88 ]
Total events: 9 (Nasal decongestant), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.72)
Total (95% CI) 536 659 100.0 % 0.98 [ 0.68, 1.40 ]
Total events: 67 (Nasal decongestant), 83 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.19, df = 6 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.90)
Test for subgroup differences: Chi2 = 0.17, df = 1 (P = 0.68), I2 =0.0%
0.01 0.1 1 10 100
Favours placebo Favours nasal decongestant
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Analysis 1.3. Comparison 1 Multi-dose decongestant versus placebo, Outcome 3 Secondary outcome:
adverse events - insomnia/difficulty sleeping.
Review: Nasal decongestants in monotherapy for the common cold
Comparison: 1 Multi-dose decongestant versus placebo
Outcome: 3 Secondary outcome: adverse events - insomnia/difficulty sleeping
Study or subgroup Nasal decongestant Placebo Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Oral
Bye 1980 9/72 25/68 43.6 % 0.25 [ 0.10, 0.58 ]
Eccles 2005 1/119 1/119 17.6 % 1.00 [ 0.06, 16.18 ]
Latte 2007 1/105 11/107 24.9 % 0.08 [ 0.01, 0.66 ]
Sperber 1989 1/10 0/23 13.9 % 7.42 [ 0.28, 198.83 ]
Subtotal (95% CI) 306 317 100.0 % 0.39 [ 0.09, 1.62 ]
Total events: 12 (Nasal decongestant), 37 (Placebo)
Heterogeneity: Tau2 = 1.04; Chi2 = 6.02, df = 3 (P = 0.11); I2 =50%
Test for overall effect: Z = 1.30 (P = 0.19)
0.01 0.1 1 10 100
Favours placebo Favours nasal decongestant
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Analysis 1.4. Comparison 1 Multi-dose decongestant versus placebo, Outcome 4 Secondary outcome:
adverse events - headache.
Review: Nasal decongestants in monotherapy for the common cold
Comparison: 1 Multi-dose decongestant versus placebo
Outcome: 4 Secondary outcome: adverse events - headache
Study or subgroup Nasal decongestant Placebo Odds Ratio Weight Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Oral
Eccles 2005 1/119 4/119 26.3 % 0.24 [ 0.03, 2.21 ]
Latte 2007 4/105 5/107 48.1 % 0.81 [ 0.21, 3.10 ]
Subtotal (95% CI) 224 226 74.4 % 0.58 [ 0.19, 1.84 ]
Total events: 5 (Nasal decongestant), 9 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.83, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
2 Topical
Eccles 2008 4/32 1/29 25.6 % 4.00 [ 0.42, 38.07 ]
Subtotal (95% CI) 32 29 25.6 % 4.00 [ 0.42, 38.07 ]
Total events: 4 (Nasal decongestant), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
Total (95% CI) 256 255 100.0 % 0.89 [ 0.23, 3.37 ]
Total events: 9 (Nasal decongestant), 10 (Placebo)
Heterogeneity: Tau2 = 0.50; Chi2 = 3.05, df = 2 (P = 0.22); I2 =34%
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Chi2 = 2.22, df = 1 (P = 0.14), I2 =55%
0.01 0.1 1 10 100
Favours placebo Favours nasal decongestant
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Analysis 2.1. Comparison 2 All doses of decongestants versus placebo, Outcome 1 Primary outcome:
subjective symptom score (mean).
Review: Nasal decongestants in monotherapy for the common cold
Comparison: 2 All doses of decongestants versus placebo
Outcome: 1 Primary outcome: subjective symptom score (mean)
Study or subgroup Nasal decongestant Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Oral
Sperber 1989 23 -6 (4) 10 -7 (2) 20.2 % 0.28 [ -0.47, 1.02 ]
Taverner 1999 24 -2.27 (0.83) 28 -2.54 (0.65) 37.2 % 0.36 [ -0.19, 0.91 ]
Subtotal (95% CI) 47 38 57.4 % 0.33 [ -0.11, 0.77 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.14)
2 Topical
Eccles 2008 29 -25.71 (16.73) 32 -35.79 (16.73) 42.6 % 0.59 [ 0.08, 1.11 ]
Subtotal (95% CI) 29 32 42.6 % 0.59 [ 0.08, 1.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.023)
Total (95% CI) 76 70 100.0 % 0.44 [ 0.11, 0.78 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.62, df = 2 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 2.59 (P = 0.0097)
Test for subgroup differences: Chi2 = 0.58, df = 1 (P = 0.45), I2 =0.0%
-2 -1 0 1 2
Favours placebo Favours nasal decongestant
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Analysis 2.2. Comparison 2 All doses of decongestants versus placebo, Outcome 2 Primary outcome:
subjective symptom score (AUC).
Review: Nasal decongestants in monotherapy for the common cold
Comparison: 2 All doses of decongestants versus placebo
Outcome: 2 Primary outcome: subjective symptom score (AUC)
Study or subgroup Nasal decongestant Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Oral
Latte 2004 24 20 (23) 24 22 (18) 18.5 % -0.10 [ -0.66, 0.47 ]
Latte 2007 107 -65.58 (77.97) 105 -77.45 (77.97) 81.5 % 0.15 [ -0.12, 0.42 ]
Subtotal (95% CI) 131 129 100.0 % 0.11 [ -0.14, 0.35 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.60, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.39)
-2 -1 0 1 2
Favours placebo Favours nasal decongestant
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Analysis 2.3. Comparison 2 All doses of decongestants versus placebo, Outcome 3 Secondary outcome:
objective NAR (mean).
Review: Nasal decongestants in monotherapy for the common cold
Comparison: 2 All doses of decongestants versus placebo
Outcome: 3 Secondary outcome: objective NAR (mean)
Study or subgroup Nasal decongestant Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Oral
Eccles 2005 115 -0.4 (0.37) 115 -0.45 (0.49) 56.4 % 0.11 [ -0.14, 0.37 ]
Subtotal (95% CI) 115 115 56.4 % 0.11 [ -0.14, 0.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.38)
2 Topical
Akerlund 1989 83 -40.06 (20.44) 19 -55.8 (24.1) 43.6 % 0.74 [ 0.23, 1.25 ]
Subtotal (95% CI) 83 19 43.6 % 0.74 [ 0.23, 1.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.84 (P = 0.0045)
Total (95% CI) 198 134 100.0 % 0.39 [ -0.22, 0.99 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 4.59, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Chi2 = 4.59, df = 1 (P = 0.03), I2 =78%
-2 -1 0 1 2
Favours placebo Favours nasal decongestant
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Analysis 2.4. Comparison 2 All doses of decongestants versus placebo, Outcome 4 Secondary outcome:
objective NAR (AUC).
Review: Nasal decongestants in monotherapy for the common cold
Comparison: 2 All doses of decongestants versus placebo
Outcome: 4 Secondary outcome: objective NAR (AUC)
Study or subgroup Nasal decongestant Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Oral
Latte 2004 24 0.091 (0.21) 24 -0.14 (0.3) 44.0 % 0.88 [ 0.28, 1.47 ]
Latte 2007 107 2.14 (0.9) 105 2.05 (0.9) 56.0 % 0.10 [ -0.17, 0.37 ]
Subtotal (95% CI) 131 129 100.0 % 0.44 [ -0.32, 1.20 ]
Heterogeneity: Tau2 = 0.25; Chi2 = 5.45, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 1.14 (P = 0.25)
-2 -1 0 1 2
Favours placebo Favours nasal decongestant
A D D I T I O N A L T A B L E S
Table 1. Study characteristics
Reference Single/multi-dose
study
Decongestant Mode of adminis-
tration
Follow-up Comments
Akerlund 1989 Single Oxymetazoline Topical 1 day -
Ferguson 1997 Single Oxymetazoline Topical 1 day Excluded from meta-analy-
ses because insufficient de-
tails were provided to stan-
dardise the results
Gronborg 1983 Single Norephedrine Oral 1 day Excluded from meta-anal-
yses because a cross-over
design was used and be-
cause norephedrine (phenyl-
propanolamine) is no longer
available on the market
Cohen 1978 Single Phenyl-
propanolamine
Oral 1 day Excluded
from meta-analyses because
phenylpropanolamine is no
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Table 1. Study characteristics (Continued)
longer available on the mar-
ket
Taverner 1999 Single Pseudoephedrine Oral 1 day -
Latte 2004 Single Pseudoephedrine Oral 1 day -
Eccles 2008 Multiple Xylometazoline Topical Max 10 days -
Eccles 2005 Multiple Pseudoephedrine Oral 3 days -
Eccles 2006 Multiple Pseudoephedrine Oral 3 days -
Eccles 2014 Multiple Pseudoephedrine Oral 3 days -
Sperber 1989 Multiple Pseudoephedrine Oral 4 days -
Bye 1980 Multiple Pseudoephedrine Oral 10 days -
Jawad 1998 Multiple Pseudoephedrine Oral 1 day -
Reinecke 2005 Multiple Oxymetazoline Topical 10 days -
Latte 2007 Multiple Pseudoephedrine Oral 4 days -
A P P E N D I C E S
Appendix 1. MEDLINE (Ovid) search strategy
1 Common Cold/
2 common cold*.tw.
3 head cold*.tw.
4 coryza.tw.
5 upper respiratory infection*.tw.
6 upper respiratory tract infection*.tw.
7 (infection* adj3 upper respiratory).tw.
8 (nasopharyngit* or rhinopharyngit*).tw.
9 nasosinusit*.tw.
10 (acute adj2 (rhinit* or rhinosinusit*)).tw.
11 (rhinorrhoea or rhinorrhoea).tw.
12 Nasal Obstruction/
13 ((nasal or nose*) adj3 (block* or obstruct* or congest* or discharge* or runny or running or stuffy or stuffed)).tw.
14 Rhinovirus/
15 rhinovir*.tw.
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16 Coronavirus Infections/
17 coronavirus/ or coronavirus 229e, human/ or coronavirus oc43, human/
18 coronavir*.tw.
19 adenoviridae/ or adenoviruses, human/
20 Adenovirus Infections, Human/
21 adenovir*.tw.
22 or/1-21
23 exp Nasal Decongestants/
24 decongestant*.tw,nm.
25 oxymetazoline.tw,nm.
26 norepinephrine.tw,nm.
27 pseudoephedrine.tw,nm.
28 phenylephrine.tw,nm.
29 xylometazoline.tw,nm.
30 tramazoline.tw.
31 Ephedrine/
32 ephedrin*.tw,nm.
33 or/23-33
34 22 and 34
Appendix 2. Embase (Elsevier) search strategy
#36 #24 AND #27 AND #35
#35 #30 NOT #34
#34 #31 NOT #33
#33 #31 AND #32
#32 ’human’/de
#31 ’animal’/de OR ’nonhuman’/de OR ’animal experiment’/de
#30 #28 OR #29
#29 random*:ab,ti OR placebo*:ab,ti OR allocat*:ab,ti OR trial:ti OR crossover*:ab,ti OR ’cross over’:ab,ti OR (doubl* NEXT/1
blind*):ab,ti
#28 ’randomized controlled trial’/exp OR ’single blind procedure’/exp OR ’double blind procedure’/exp OR ’crossover procedure’/exp
#27 #25 OR #26
#26 oxymetazoline:ab,ti OR norepinephrine:ab,ti OR pseudoephedrine:ab,ti OR phenylephrine:ab,ti AND xylometazoline:ab,ti OR
tramazoline:ab,ti OR ephedrin*:ab,ti OR (intranasal NEAR/2 corticosteroid*):ab,ti
#25 ’decongestive agent’/exp AND [embase]/lim79259
#24 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR
#12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22
OR #2384658
#23 adenovir*:ab,ti AND [embase]/lim35904
#22 ’human adenovirus’/exp OR ’human adenovirus infection’/de
#21 coronavir*:ab,ti
#20 ’coronavirus’/de OR ’human coronavirus nl63’/de
#19 rhinovir*:ab,ti
#18 ’human rhinovirus’/de OR ’rhinovirus infection’/de
#17 ((nasal OR nose*) NEAR/3 (block* OR congest* OR obstruct* OR discharg* OR runny OR running OR stuffy OR stuffed)):
ab,ti
#16 ’nose congestion’/de OR ’nose infection’/de
#15 rhinorrhoea:ab,ti OR rhinorrhea:ab,ti
#14 ’rhinorrhea’/de
#13 sneez*:ab,ti
#12 ’sneezing’/de
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#11 ’common cold symptom’/de
#10 (acute NEAR/2 (rhinit* OR rhinosinusit*)):ab,ti
#9 ’rhinosinusitis’/de
#8 rhinopharyngit*:ab,ti OR nasopharyngit*:ab,ti
#7 ’rhinopharyngitis’/de
#6 (infection* NEAR/3 ’upper respiratory’):ab,ti
#5 ’upper respiratory tract infection’:ab,ti OR ’upper respiratory tract infections’:ab,ti OR urti:ab,ti
#4 ’upper respiratory tract infection’/de OR ’viral upper respiratory tract infection’/de
#3 ’head cold’:ab,ti OR ’head colds’:ab,ti OR coryza:ab,ti
#2 ’common cold’:ab,ti OR ’common colds’:ab,ti
#1 ’common cold’/de
Appendix 3. CINAHL (Ebsco) search strategy
S34 S23 and S33
S33 S24 or S25 or S26 or S27 or S28 or S29 or S30 or S31 or S32
S32 (MH “Quantitative Studies”)
S31 TI placebo* OR AB placebo*
S30 (MH “Placebos”)
S29 TI random* OR AB random*
S28 (MH “Random Assignment”)
S27 TI ((singl* or doubl* or tripl* or trebl*) W1 (blind* or mask*) ) OR AB ( (singl* or doubl* or tripl* or trebl*) W1 (blind* or
mask*))
S26 TI clinic* W1 trial* OR AB clinic* W1 trial*
S25 PT clinical trial
S24 (MH “Clinical Trials+”)
S23 S17 and S22
S22 S18 or S19 or S20 or S21
S21 TI intranasal N2 corticosteroid* OR AB intranasal N2 corticosteroid*
S20 TI (oxymetazoline or norepinephrine or pseudoephedrine or phenylephrine or xylometazoline or tramazoline or ephedrin* ) OR
AB ( oxymetazoline or norepinephrine or pseudoephedrine or phenylephrine or
xylometazoline or tramazoline or ephedrin*)
S19 TI decongestant* OR AB decongestant*
S18 (MH “Vasoconstrictor Agents, Nasal+”) OR (MH “Ephedrine”) OR (MH “Phenylephrine”)
S17 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16
S16 TI (rhinovir* or adenovir*) OR AB (rhinovir* or adenovir*)
S15 TI coronavir* OR AB coronavir*
S14 (MH “Coronavirus Infections”)
S13 (MH “Coronavirus”)
S12 TI ((nasal or nose*) N3 (block* or obstruct* or congest* or discharg* or runny or running or stuffy or stuffed)) OR AB ((nasal or
nose*) N3 (block* or obstruct* or congest* or discharg* or runny or
running or stuffy or stuffed))
S11 (MH “Nasal Obstruction”)
S10 TI (sneez* or rhinorrhea* or rhinorrhoea*) OR AB (sneez* or rhinorrhea* or rhinorrhoea*)
S9 (MH “Sneezing”)
S8 TI (nasopharyngit* or rhinopharyngit*) OR AB (nasopharyngit* or rhinopharyngit*)
S7 TI (acute N2 (rhinit* or rhinosinusit* or nasosinusit*)) OR AB (acute N2 (rhinit* or rhinosinusit* or nasosinusit*))
S6 (MH “Rhinosinusitis”)
S5 TX (upper respiratory infection* or upper respiratory tract infection* or urti) OR AB (upper respiratory infection* or upper
respiratory tract infection* or urti)
S4 TI coryza OR AB coryza
S3 TI head cold* OR AB head cold*
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S2 TI common cold* OR AB common cold*
S1 (MH “Common Cold”)
Appendix 4. LILACS (BIREME) search strategy
(MH:“Common Cold” OR “Resfriado Común” OR “Resfriado Comum” OR “Coriza Aguda” OR Catarro OR coryza OR “upper
respiratory tract infection” OR “upper respiratory tract infections” OR “upper respiratory infection” OR “upper respiratory infections”
OR “Infecciones del Tracto Respiratorio Superior” OR “Infecciones de las Vías Respiratorias Superiores” OR “Infecções do Trato Respi-
ratório Superior” OR “Infecções do Sistema Respiratório Superior” ORMH:Nasopharyngitis ORNasofaringitis ORNasofaringite OR
nasophayrngit$ or rhinopharyngit$ OR nasosinusit$ OR rhinosinusit$ OR rhinit$ OR rinit$ OR MH:sneezing OR Estornudo OR
Espirro OR rhinorrhea OR rhinorrhoea OR Rinorrea OR Rinorréia OR “blocked nose” OR “nasal obstruction” OR “runny nose” OR
“running nose” OR “nasal congestion” OR “nasal discharge” OR “stuffy nose” OR “stuffed nose” OR “stuffy nose” ORMH:rhinovirus
OR rhinovir$ ORMH:“Coronavirus Infections” ORMH:Coronavirus ORMH:“Coronavirus 229E, Human” ORMH:“Coronavirus
OC43, Human” OR MH:“Coronavirus NL63, Human” OR MH:“Adenovirus Infections, Human” ORMH:“Adenoviruses, Human”
OR adenovir$) AND (MH:“Nasal Decongestants” ORMH:D27.505.954.411.793.610$ OR MH:D27.505.954.796.560$ OR “De-
scongestionantes Nasales” OR “Descongestionantes Nasais” ORDescongestionantes OR “Vasoconstrictores Nasales” OR descongestio-
nantes OR “Vasoconstritores Nasais” OR decongestant$ OR oxymetazolin$ OROximetazolina OR norepinephrine ORNorepinefrina
OR pseudoephedrine OR Seudoefedrina OR Pseudoefedrina OR Isoephedrine OR xylometazoline OR MH:Ephedrine OR efedrina
OR “intranasal corticosteroid” OR “intranasal corticosteroids”)
Appendix 5. Web of Science (Thomson Reuters) search strategy
#16 #15 AND #12
DocType=All document types; Language=All languages;
#15 #14 OR #13
DocType=All document types; Language=All languages;
#14 Topic=((single or double) NEAR/1 blind*) OR Title=(trial)
DocType=All document types; Language=All languages;
#13 Topic=(random* or placebo* or “clinical trial$” or allocat*) OR Title=(trial)
DocType=All document types; Language=All languages;
#12 #11 AND #7
DocType=All document types; Language=All languages;
#11 #10 OR #9 OR #8
DocType=All document types; Language=All languages;
#10 Topic=(intranasal NEAR/2 corticosteroid$)
DocType=All document types; Language=All languages;
#9 Topic=(oxymetazoline or norepinephrine or pseudoephedrine or phenylephrine or xylometazoline or tramazoline or ephedrin*)
DocType=All document types; Language=All languages;
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(Continued)
#8 Topic=(nasal NEAR/2 decongestant$)
DocType=All document types; Language=All languages;
#7 #6 OR #5 OR #4 OR #3 OR #2 OR #1
DocType=All document types; Language=All languages;
#6 Topic=(rhinovir* or coronavir* or adenovir*)
DocType=All document types; Language=All languages;
#5 Topic=((nasal or nose$) NEAR/3 (block* or congest* or discharg* or runny or running or stuffy or stuffed))
DocType=All document types; Language=All languages;
#4 Topic=(acute NEAR/2 rhinit*)
DocType=All document types; Language=All languages;
#3 Topic=(nasopharyngit* or rhinopharyngit* or nasosinusit* or rhinosinusit* or sneez* or rhinorrhea or rhinorrhoea)
DocType=All document types; Language=All languages;
#2 Topic=(infection$ NEAR/3 “upper respiratory”)
DocType=All document types; Language=All languages;
#1 Topic=(“common cold” or “common colds” or “head cold$” or coryza)
DocType=All document types; Language=All languages;
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The review differs from the protocol (Ta’i 2012) in the following sections.
In Methods, Data collection and analysis and Unit of analysis issues we specified how we handled data from trials that included more
than one treatment arm. If the treatment arm was similar (e.g. different doses of the same nasal decongestant), we combined data from
these treatment arms and compared this group to the control group, as recommended in section 7.7.3.8 and Table 7.7a of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We added randomised cross-over trials to the inclusion criteria because cross-over studies with adequate randomisation can be regarded
as RCTs. We also specified how we handled data from trials using cross-over designs; results of these studies were not included in the
meta-analysis, but were reported narratively.
In Methods, Data collection and analysis and Data synthesis we specified the rule-of-thumb for effect sizes to facilitate interpretation
of the SMD as described in section 12.6.2 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). In the
same section, we also added a description of how we assessed the overall quality of the evidence. We used the GRADE (Grading of
Recommendations Assessment, Development and Evaluation) approach, which gives an indication of the confidence that can be placed
in the estimate of treatment effect. The effect estimates and GRADE ratings were summarised in the ’Summary of findings’ tables. We
only summarised results for which more than one study was available. We used the GRADEprofiler tool (GRADEpro) and followed
the advice from the GRADE Handbook (Schünemann 2009).
We also analysed single and multi-dose studies together, whereas in the protocol it was stated that we would analyse them separately
(Ta’i 2012). Clinically it could be argued that a single or multiple-dose nasal decongestant would have a similar effect, although it may
not be as long lasting from a single dose. We expect that up to three hours after dosing, the effect of a single dose is clinically not
expected to be inferior to multiple doses. Therefore we combined single and multiple doses up to three hours after dosing.
Based on feedback from the statistical editor we decided to use a random-effects model for all meta-analyses. Nevertheless, we reported
whether using a fixed-effect or random-effects model affected the results (see Methods; Data collection and analysis; Data synthesis).
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